

Craig Frank John Munns

Curriculum Vitae

PERSONAL DETAILS

Name: Craig Frank John MUNNS

Qualifications:	MBBS	University of Queensland	1992
	FRACP	RACP	2001
	PhD	University of Queensland	2004

PhD Thesis: "Role of the Short Stature Homeobox Gene in Skeletal Growth and Development".

E mail: craig.munns@health.nsw.gov.au

Current Positions: Senior Staff Specialist Bone & Mineral Medicine and Endocrinology
Section Head Bone & Mineral Medicine
Section Head Endocrine Laboratory Services
The Children's Hospital at Westmead
Sydney, NSW, Australia

Clinical Trials Lead
Kids Research
The Children's Hospital at Westmead
Sydney, NSW, Australia

Professor of Paediatric Bone and Mineral Medicine
Paediatrics and Child Health
Sydney Medical School
University of Sydney
Sydney, NSW, Australia

Honorary Professor
Department of Clinical Medicine
Faculty of Medicine and Health Sciences
Macquarie University
Sydney, NSW, Australia

CAREER HISTORY

Previous Appointments

- 2016-2020 Clinical Program Director - Diagnostic Services
The Children's Hospital at Westmead
Sydney, NSW, Australia
- 2002-2004 Clinical Associate in Genetic and Metabolic Bone Disease
Genetics Unit, Shriners Hospital for Children, Montreal, Canada.
- 2002 Royal Children's Hospital Foundation/Cressbrook Clinical Research
Fellow in Endocrinology
Royal Children's Hospital and District Health Service, Brisbane,
Australia.
Part-time Staff Specialist
Department of Endocrinology and Diabetes, Mater Children's Hospital,
South Brisbane, Australia.
Visiting Medical Officer
Department of Emergency Medicine, Mater Children's Hospital, South
Brisbane Australia.
- 2001 Visiting Medical Officer
Department of Emergency Medicine, Mater Children's Hospital, South
Brisbane Australia.
- 1999 -2001 Royal Children's Hospital Foundation/Cressbrook Clinical Research
Fellow in Endocrinology, Royal Children's Hospital and District Health
Service, Brisbane, Australia.
- 1996 - 1999 Paediatric Registrar
Royal Children's Hospital, Brisbane, Australia.
- 1995 - 1996 Paediatric Senior House Officer
Royal Children's Hospital, Brisbane, Australia.
- 1994 - 1995 Senior House Officer
Gladstone Hospital, Gladstone, Australia.
- 1993 Intern
Royal Brisbane Hospital
Brisbane, Australia. Queensland Department of Health Scholarship
holder.

UNIVERSITY OF SYDNEY

2018 – Current	Conjoint Professor of Paediatric Bone and Mineral Medicine, Sydney Medical School
2010 – 2017	Conjoint Associate Professor, Sydney Medical School
2004 – 2010	Conjoint Senior Lecturer, Sydney Medical School

MACQUARIE UNIVERSITY

2018 – Current	Honorary Professor, Faculty of Medicine and Health Sciences
----------------	---

TEACHING

University of Sydney Summer Students

- Craig Coorie 2014
- Daniel Yeo 2014
- Craig Coorie 2013
- Jenny Le Quan 2013

Masters Supervision

- Paul Tannous – University of Notre Dame – Awarded 2020
- Komal Vora - University of Sydney – Awarded 2021

PhD Supervision

- Pascal Bridge – University of Sydney – Awarded 2012
- Verity Pacey – University of Sydney - Awarded 2014
- Denise Brookes – University of Queensland - Awarded 2014
- Kim Ramjan – University of Sydney – Awarded 2017
- Anna Middleton – University of Sydney – Awarded 2019
- Muhd Kamal Muhd Jamil – University of Sydney – Awarded 2020
- Bhavna Payde – University of Sydney – Awarded 2020
- Julie Briody - University of Sydney
- Alison Wesley – University of Sydney
- Alexandra O'Donohue – University of Sydney
- Karissa Ludwig – University of Sydney / McGill University, Montreal, Canada

Honours Supervision

- Jessica Mumford – University of New England – Completed 2014

Diploma of Child Health Lecture, Children's Hospital at Westmead

- Rickets 2016 – Current

Paediatric Endocrinology Fellow Schools

- Asia Pacific Paediatric Endocrine Society – 2006 – Current (Annual)
- Indian Society Paediatric and Adolescent Endocrinology – 2015, 2019
- *Australasian Paediatric Endocrine Group 2021*

SOCIETIES

American Society of Bone and Mineral Research (ASBMR).

- Editor JBMR Plus

Asia Pacific Paediatric Endocrinology Society (APPES).

- Honorary Treasure 2006 – 2018
- Scientific Committee and Faculty of Fellow School 2006 – 2021

Australasian Paediatric Endocrine Group (APEG).

- Chair ASM Scientific Committee 2008 – 2012
- Chair Bone and Mineral Working Group 2012 – Present

Australian and New Zealand Bone and Mineral Society (ANZBMS).

- Co-Chair Scientific Committee 2020 – 2021
- Therapeutics Committee 2011 – Present

Endocrine Society

European Society of Paediatric Endocrinology (ESPE)

International Bone and Mineral Society (IBMS).

International Conference on Children's Bone Health

- Scientific Committee 2015, 2017, 2019
- Executive Steering Committee 2019 – Present

Vitamin D Workshop

- Joint organising Committee 2019 – 2020

COMMITTEE APPOINTMENTS & RESPONSIBILITIES

The Children's Hospital at Westmead

- Head of Laboratory Services, Department of Endocrinology and Diabetes
- Head of Bone and Mineral Medicine, Department of Endocrinology and Diabetes
- Head of Clinical Research and Executive Committee Member, Children's Centre for Bone and Musculoskeletal Health, Kids Research Institute 2015 – Current
- SCHN Workforce Advisory Committee 2018 – Current
 - Medical Lead – Doctor in Five Years Project 2019
 - Medical Lead – Research at SCHN 2021
- SCHN Physician Site Champion – I-ACT 2019 – Current
- Paediatrics and Youth Health Community of Practice (NSW Health) 2020 – Current
- Clinical Trials Community of Practice (Office of Health and Medical Research NSW Health) 2000 – Current
- SCHN Human Research Ethics Committee – Executive Representative 2021 – Current
- SCHN representative on New South Wales Health Pathology Clinical Council Board 2016 – 2021
- SCHN Performance and Planning Committee 2016 – 2020
- SCHN Information Strategy Executive Committee 2016 – 2020

University of Sydney

- University of Sydney; Sydney Arthritis & Musculoskeletal Research Network– Steering Committee 2015 – 2017
- University of Sydney; Sydney Health Partners SydMSK Alliance Steering Group 2018 – Present
- University of Sydney; Sydney Health Partners Clinical Trials Community of Practice 2020 – Present

New South Wales Health Pathology

- Executive Steering Committee – State-wide Laboratory Information System 2019 - 2021
- SCHN representative on NSW Health Pathology Clinical Council Board 2016 - 2021

Scientific Societies

- Asia Pacific Paediatric Endocrinology Society (APPES) Honorary Treasurer 2006 – 2018
- Asia Pacific Paediatric Endocrinology Society (APPES) Scientific Committee and Faculty of Fellow School 2006 – Current
- ANZBMS Therapeutic Committee 2011 – Current
- ANZBMS Co-Chair Program Organising Committee 2020 – 2021
- Australasia Paediatric Endocrine Group (APEG) Bone and Mineral Subcommittee Chair 2012 – Current
- APEG Scientific Committee, Member 2007 – 2008 and Chair 2009 – 2013.

- International Federation of Musculoskeletal Research Societies (IFMRS) Big Data Working Group (ANZBMS Representative) – 2013 – Current
- International Conference of Children's Bone Health (ICCBH) Scientific Committee – 2015 – Current.
- International Conference of Children's Bone Health (ICCBH) Executive 2019 – Present
- Vitamin D Workshop Joint organising Committee 2019 – 2020

NSW Health

- NSW Musculoskeletal Network Executive Agency for Clinical Innovation 2007- Current

Advocacy and Philanthropic Groups

- Osteoporosis Australia Medical and Scientific Advisory Committee 2008 – 2016
- Standards of Care Committee - Nemaline and related myopathies 2008 – 2010
- Caring and Living as Neighbours (CLAN) Technical Advisory Committee: Bone and Mineral Consultant 2010 – Current
- Sticks and Stones (Philanthropic Group) – Director 2015 – Current

Royal Australasian College of Physicians'

- National Examiner 2011 – 2014
- Local Examiner 2005 – Current

Industry Advisory Boards and Consultancies

- Early Recognition of Hypophosphatasia (HPP) Advisory Board (Alexion International)
- Hypophosphatasia (HPP) Treatment Monitoring Guidance Advisory Board (Alexion International)
- Kyowa Kirin Asia Pacific Advisory Board for X-linked Hypophosphataemic Rickets (Chair) 2020
- Kyowa Kirin Australian Advisory Board for X-linked Hypophosphataemic Rickets (Chair) 2020
- Ipsen Palovarotene Advisory Board 2020
- Asfotase alfa in Hypophosphatasia Alexion Australia advisory board
- Consultant for Alexion Australia
- Consultant for Sanofi
- Consultant for Kyowa Kirin

AWARDS

- 2019 Selected for NSW Health Clinical Excellence Commission Executive Leadership Program
- 2015 - Best Oral Communication Award. 7th International Conference on Children's Bone Health. Salzburg, Australia
- 2012 - The Henry Kilham Award for Outstanding Contribution to Postgraduate Teaching. The Children's Hospital at Westmead
- 2010 - Kaichi Kida Award for Best Oral Presentation. Asia Pacific Paediatric Endocrine Society.
- 2002 - Royal Children's Hospital Foundation/Woolworth's Traveling Scholarship to undertake advanced training in Paediatric Genetic and Metabolic Bone Disorders.
- 2001 - Australasian Paediatric Endocrine Group (APEG) Young Investigator of the Year. Paper title: "The Spectrum of *SHOX* Haploinsufficiency Disorder: Diagnostic Markers."
- Asia Pacific Paediatric Endocrine Society travel scholarship to attend "Paediatric Endocrinology Montreal 2001".
- Serono Postgraduate Travel Award 2001.
- 1999 - Australia & New Zealand Bone & Mineral Society Travel Grant to attend the 2000, 10th Annual Scientific Meeting.
- Endocrine Society of Australia Travel Award to attend the International Congress of Endocrinology.
- Endocrine Society of Australia / Serono Postgraduate Travel Award to attend the Serono Symposium USA.

RESEARCH FUNDING

Competitive Research Grants and Investigator Initiated Grants TOTAL \$3,480,700

1. Pacey V, Simm P, **Munns CF**. APEG 2020 Sandoz Research Grant. Development of Allied Health Management Guidelines for Children and Adolescents with Osteogenesis Imperfecta. 2020. Co-investigator. \$15,000.
2. Lee L, Biggin A, Schindeler A, Gunton J, **Munns C**. APEG 2020 Novo Nordisk Research Grant. Generating novel AAV vectors for preclinical modelling of gene therapy treatment for diabetes and other endocrine disorders. 2020. Co-investigator. \$15,000.
3. Biggin A, **Munns CF**. Clinical registry to evaluate treatment outcomes in paediatric X-linked Hypophosphataemic Rickets (XLH) in Australia. 2019. Investigator initiated research grant. \$75,000.
4. Biggin A, **Munns C**, Schindeler A. APEG 2019 APEG Research Grant. Understanding the genetic and cellular mechanisms of reduced bone health caused by obesity. \$25,000.
5. Biggin A, Ambler G, Srinivasan S, McGuire A, Craig M, Benetiz P, Donoghue K, **Munns CF**. APEG Patient Registry Grant. 2019. \$100,000.
6. **Munns CF**, Simm P, Ebeling P, Milat F, Duncan E, Biggin A, Siafarikas A, Crafter S, Coates P, Clifton-Bligh R, Elliott E, Teutsch S. APSU Prevalence Study of X-linked Hypophosphataemic Rickets. 2019. Principle Investigator. Initiated research grant. \$75,000.
7. **Munns CF**, Simm P, Savarirayan R, Ebeling P, Duncan E, Hooper H, Widmer R, Hibbert S, McGill J, Siafarikas A, Tham E, Elliott E, Teutsch S. APSU Prevalence Study of Hypophosphatasia. 2019. Principle Investigator. Investigator initiated research grant. \$75,000.
8. Bernitez-Aguirre P, **Munns CF**, Donoghue K. Diabetes Australia Research Program. Effect of Childhood Type 1 Diabetes on Bone Health: Is abnormal bone development during childhood related to increased adult fracture risk? – 2016. \$60,000
9. L Nicholson, V Pacey, L Tofts, **C Munns**. Clinical characteristics of children with generalised joint hypermobility, Arthritis Australia, Zimmer Australia Grant & Arthritis Australia and State and Territory Affiliate Grant - 2015. \$10,000
10. **Munns CF**, Koyyalamudi SR, Biggin A, Lee J, Wiley V, Padhye B. Assessment of neonatal vitamin D status using dried blood spots: epidemiology of neonatal vitamin D deficient and association with childhood cancer and type 1 diabetes mellitus. Kids Research Institute – 2015 - 2016. \$180,000.
11. Zacharin M, **Munns CF**, North K. Thrasher Foundation: Clinical trial of Zoledronic acid in children and adolescents with Duchenne(DMD) . 2014. US\$86,571.

12. **Munns CF**, Biggin A. OA/ANZBMS Clinical Grant. A fracture prevention service to optimise bone health and prevent osteoporosis in the paediatric population – 2013. \$50,000
13. L Nicholson, V Pacey, L Tofts, **C Munns**. Clinical characteristics of children with generalised joint hypermobility, Arthritis Australia, Barbara Cameron Memorial Grant – 2013. \$15,000
14. **Munns CF**, North K, Clarke N, Rose K, Fitzgerald D, Selvadurai H. A Foundation Building Strength. Whole Body Vibration Training for Nemaline Myopathy. – 2012. US\$86,412.
15. **Munns CF**. Thyne Reid Foundation. Osteogenesis Imperfecta Fellow. 2011-2012. \$264,000.
16. **Munns CF**, Zacharin M, North K. Muscular Dystrophy Association for Research Grant: Clinical trial of Zoledronic acid in children and adolescents with Duchenne(DMD) . 2011-2014. US\$250,000.
17. NHMRC Project Grant 1008226. Verge C, Hameed S, Jaffe A, Peat J, Selvadurai H, Cooper P, Hilton J, Donaghue K, **Munns CF**, Crock P. Cystic Fibrosis - Insulin Deficiency, Early Action (CFIDEA). 2 years 2011-2012. \$381,530
18. NHMRC Project Grant 632532. Cowell CT, Little DG, **Munns CF**, Foster B, Zacharin M. Bisphosphonate Treatment of Childhood Femoral Head Avascular Necrosis due to Perthes Disease. 5 years 2010-2014. \$1,305,625.
19. Zacharin M, **Munns CF**, Kornberg A, North K, Little D. Pfizer Endocrine Care Paediatric Research Grant. Clinical trial of Zoledronic acid (Aclasta) in children and adolescents with Duchenne muscular dystrophy. 2010, 1 year. \$40,000.
20. Simm P, **Munns CF**, Cowell C, North K, Little D. Pfizer Endocrine Care Paediatric Research Grant. Bone Health in Neurofibromatosis Type I. 2009, 1 year. \$55,000.
21. Ramjan K, **Munns CF**, Garnet S, Cowell C. Pfizer Endocrine Care Paediatric Research Grant. Flabulous: The effect of whole body vibration training on insulin sensitivity in adolescents. 1 year. 2009, \$55,000.
22. Ramjan K, **Munns CF**, Garnet S, Cowell C. The effect of whole body vibration training on insulin sensitivity in adolescents. Novo Nordisk Regional Research Grant. \$10,000.
23. NHMRC Project Grant 402714. Little DG, **Munns CF**. Role of Osteoclasts during the early stages of bone healing. 3 years 2006-2008. \$303,875.
24. **Munns CF**, Glass I, Batch J. APEG Novonordisk Research Grant. Role of the Short Stature Homeobox Gene in Skeletal Growth and Development. 1 year 2000. \$15,000.

Collaborative Industry Grants

1. **Munns CF**, Biggin A. An Observational, Longitudinal, Prospective, Long-Term Registry of Patients with Hypophosphatasia (Alexion Pharmaceuticals Inc). 2017-Ongoing. Principle Investigator.
2. **Munns CF**, Biggin A. Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children with Osteogenesis Imperfecta (Amgen Ltd). 2014-Ongoing. Principle Investigator.
3. **Munns CF**, Biggin A. A Retrospective, Non-Interventional Epidemiologic Study of the Natural History of Patients with Juvenile-Onset Hypophosphatasia (HPP) (Alexion Pharmaceuticals Inc). 2015-Ongoing. Principle Investigator.
4. **Munns C**, Cowell C, Woods N, Moody P, Hayes E. Bio-Ceuticles. Safety and Effectiveness of Stoss Therapy in the Treatment of Vitamin D Deficiency. 2010-2012. Principle Investigator
5. **Munns C**, Cowell C, Little D, Foster B, Zacharin C. Novartis. Bisphosphonate Treatment of Childhood Femoral Head Avascular Necrosis due to Perthes Disease. 5 years 2010-2014. Principle Investigator
6. Zacharin M, **Munns CF**, Kornberg A, North K, Little D. Novartis. Clinical trial of Zoledronic acid (Aclasta) in children and adolescents with Duchenne muscular dystrophy. 2010-2019. Principle Investigator
7. **Munns CF**, Biggin A, Little D. A multicentre, randomised, double-blind, placebo controlled efficacy and safety trial of intravenous zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids. (Novartis). 2011-2017. Principle Investigator.
8. **Munns CF**, Biggin A, Little D. A 1-year, multicentre, open-label extension to CZOL446H2337 to evaluate safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions. (Novartis). 2013-2017. Principle Investigator.
9. **Munns CF**, Biggin A, Poon M. A Randomised, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemic (XLH) (ultragenyx). 2017-2019. Principle Investigator.
10. Bishop N, Sillence D, **Munns CF**. Alliance for Better Bone Health (Procter and Gamble, and Sanofi-Novartis). A Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel Group Study of One-Year Duration followed by 2 years of Open Label Treatment to Determine the Safety and efficacy of Orally Administered 2.5mg or 5.0mg Daily Risedronate, in Children with Osteogenesis Imperfecta. 2005-2010. Co-investigator

RESEARCH OUTPUT

- (i) **Peer-review journal articles:** At 17 years post PhD, total 138 publications (55 in last 5 yrs); 20 top 5%, 33 top 10% FWCI. Scopus H index 40. Cited >4920 times. 12 articles cited >100 times. Scopus May 2021.

Five best publications from the past 10 years

1. **Munns CF**, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, Michigami T, Tiosano D, Mughal MZ, Mäkitie O, Ramos-Abad L, Ward L, DiMeglio LA, Atapattu N, Cassinelli H, Braegger C, Pettifor JM, Seth A, Wasagu Idris H, Bhatia V, Fu J, Goldberg G, Säwendahl L, Khadgawat R, Pludowski P, Maddock J, Hyppönen E, Oduwole A, Frew E, Aguitar M, Tulchinsky T, Butler G, Höglér W. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. *J Clin Endocrinol Metab.* 2016 Feb;101(2):394-415. [Cited 409X, FWCI=29.15; top 1%, Alt 16]

The first international consensus document on nutritional rickets. This document has led to a change in practice in many nations including Australia for the prevention and management of nutritional rickets.

2. Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszú E, Lane JM, Lorenc R, Mäkitie O, **Munns CF**, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2013 Oct 26;382(9902):1424-32. [Cited 118X, FWCI=15.57; top 1%, Alt 75]

The first international randomised controlled trial of bisphosphonates in children. This has led to a change in management for children with both primary and secondary bone fragility. I led this study at CHW and internationally we were the leading recruitment site for this study.

3. Imel EA, Glorieux FH, Whyte MP, **Munns CF**, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Höglér W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. *Lancet*, 2019 Jun 15;393(10189):2416-2427. [Cited 56X, FWCI=16.92; top 1%, Alt 64]

The first phase 3 RCT of Burosumab in children with X-linked hypophosphataemic rickets. The article will result in a paradigm shift in the management of this debilitating disorder. I was the Australian PI for this study and CHW was the leading recruitment site internationally for this study.

4. **Munns CF**, Simm PJ, Rodda CP, Garnett SP, Zacharin MR, Ward LM, Geddes J, Cherian S, Zurynski Y, Cowell CT; on behalf of the APSU Vitamin D Study Group. Incidence of vitamin D deficiency rickets among Australian

children: an Australian Paediatric Surveillance Unit study. *Med J Aust.* 2012 Apr 16;196(7):466-468. [Cited 79X, FWCI=5.46; top 3%; Alt 9]

The first Australia surveillance study of nutritional rickets. It led to a similar study being performed in New Zealand, and to the development of Australasian and Global statements on the prevention and treatment of nutritional rickets.

5. Zacharin M, Lim A, Gryllakis J, Siafarikas A, Jefferies C, Briody J, Heather N, Pitkin J, Emmanuel J, Lee KJ, Wang X, Simm PJ, **Munns CF**. Randomised controlled trial evaluating the use of Zoledronic acid in Duchenne Muscular Dystrophy. *J Clin Endocrinol Metab.* 2021 May 6:dgab302. doi: 10.1210/clinem/dgab302. Online ahead of print. [Yet to be recorded on Scopus]

The first randomised controlled trial of bisphosphonates in Duchenne Muscular Dystrophy and showed an increase in BMD and trend towards a reduction in primary vertebral compression fracture rate. This is an important study for both the impact it will have on the field of paediatric bone and mineral medicine and as an example of the collaborative Bone and Mineral Network that I have built in Australia.

Articles cited over 100 times

1. **Munns CF**, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, Michigami T, Tiosano D, Mughal MZ, Mäkitie O, Ramos-Abad L, Ward L, DiMeglio LA, Atapattu N, Cassinelli H, Braegger C, Pettifor JM, Seth A, Wasagu Idris H, Bhatia V, Fu J, Goldberg G, Säwendahl L, Khadgawat R, Pludowski P, Maddock J, Hyppönen E, Oduwole A, Frew E, Aguitar M, Tulchinsky T, Butler G, Högl W. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. *J Clin Endocrinol Metab.* 2016 Feb;101(2):394-415. [Cited 409X, FWCI=29.15; top 1%]
2. **Munns CF**, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. *J Bone Miner Res.* 2004 Nov;19(11):1779-86.[Cited 191X, FWCI=4.28; top 5%]
3. **Munns C**, Zacharin MR, Rodda CP, Batch JA, Morley R, Cranswick NE, et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. *Med J Aust.* 2006 Sep 4;185(5):268-72. [Cited 184X, FWCI=11.52; top1%]
4. Plotkin H, Rauch F, Zeitlin L, **Munns C**, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. *J Clin Endocrinol Metab.* 2003 Oct;88(10):4569-75. [Cited 169X, FWCI=3.21; top 7%]

5. Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, **Munns CF**, Lazaretti-Castro M, Giustina A, Bilezikian J. Skeletal and extra-skeletal actions of vitamin D: Current evidence and outstanding questions. *Endocr Rev.* 2019 Aug 1;40(4):1109-1151. [Cited 160X, FWCI=13.90; top1%]
6. Bönnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, Muntoni F, Sewry C, Bérout C, Mathews KD, Moore SA, Bellini J, Rutkowski A, North KN; Members of International Standard of Care Committee for Congenital Muscular Dystrophies. Diagnostic approach to the congenital muscular dystrophies. *Neuromuscul Disord.* 2014 Apr;24(4):289-311. [Cited 155X, FWCI=9.64; top 1%]
7. Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, **Munns CF**, Shaw N. Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD 2013 Pediatric Official Positions. *J Clin Densitom.* 2014 Apr-Jun;17(2):275-80. [Cited 134X, FWCI 8.24; top 2%]
8. Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszú E, Lane JM, Lorenc R, Mäkitie O, **Munns CF**, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2013 Oct 26;382(9902):1424-32. [Cited 118X, FWCI=15.57; top 1%]
9. **Munns CF**, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. *J Bone Miner Res.* 2005 Jul;20(7):1235-43.[Cited 112X, FWCI=4.55; top 4%]
10. Paxton GA, Teale GR, Nowson CA, Mason RS, McGrath JJ, Thompson MJ, Siafarikas A, Rodda CP, **Munns CF**. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement.; Australian and New Zealand Bone and Mineral Society; Osteoporosis Australia. *Med J Aust.* 2013 Feb 18;198(3):142-3. [Cited 111X, FWCI=13.21; top 1%]
11. Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, **Munns C**, Wenket D, Zeitler P. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. *J Clin Densitom.* 2008 Jan-Mar;11(1):22-8. [Cited 106X, FWCI=4.19; top 5%]
12. Land C, Rauch F, **Munns CF**, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. *Bone.* 2006 Oct;39(4):901-6. [Cited 103X, FWCI=3.49; top 7%]

List of all cited publications

1. Ward L, Choudhury A, Alos N, Cabral DA, Rodd C, Sbrocchi A, Padidela R, Shaw NJ, Hosszu E, Kostik M, Alexeeva E, Thandrayen K, Shenouda N, Jaremko JL, Sunkara G, Sayyed S, Aftring RP, **Munns CF**. Zoledronic acid versus placebo in pediatric glucocorticoid-induced osteoporosis: A randomized double-blind phase 3 trial. *J Clin Endocrinol Metab*. 2021. In Press.
2. Zacharin M, Lim A, Gryllakis J, Siafarikas A, Jefferies C, Briody J, Heather N, Pitkin J, Emmanuel J, Lee KJ, Wang X, Simm PJ, **Munns CF**. Randomised controlled trial evaluating the use of Zoledronic acid in Duchenne Muscular Dystrophy. *J Clin Endocrinol Metab*. 2021 May 6:dgab302. doi: 10.1210/clinem/dgab302. Online ahead of print.
3. Thacher TD, Sempos CT, Durazo-Arvizu RA, Fischer PR, **Munns CF**, Pettifor JM. The validity of serum alkaline phosphatase to identify rickets in Nigerian children on a calcium-deprived diet. *J Clin Endocrinol Metab*. 2021 May. Dgab328. doi:10.1210/clinem/dgab328. Online ahead of print.
4. Sempos CT, Durazo-Arvizu RA, Fischer PR, **Munns CF**, Pettifor JM, Thacher TD. Serum 25-hydroxyvitamin D requirements to prevent nutritional rickets in Nigerian children on a low-calcium diet – a multivariable reanalysis. *Am J Clin Nutr*. 2021 March: nqab048. doi: 10.1093/ajcn/nqab048. Online ahead of print.
5. Rushworth RL, Gouvoussis N, Goubar T, Maguire A, **Munns CF**, Neville KA, Torpy DJ. Acute illness in children with secondary adrenal insufficiency. *Clin Endocrinol (Oxf)*. 2021 Feb 5. doi: 10.1111/cen.14427. Online ahead of print.
6. Padidela R, Whyte MP, Glorieux FH, **Munns CF**, Ward LM, Nilsson O, Portale AA, Simmons JH, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högl W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Williams A, Nixon A, Sun W, Chen A, Skrinar A, Imel EA. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. *Tissue Int*. 2021 May;108(5):622-633.
7. Attard C, Monagle PT, d'Udekem Y, Mackay MT, Briody J, Cordina T, Hassan EB, Simm P, Rice K, Ignjatovic V; ANZ Fontan Registry Research Group. Long-term outcomes of warfarin versus aspirin after Fontan Surgery. *J Thorac Cardiovasc Surg*. 2021 Jan. Online ahead of print.
8. Ireland PJ, Savarirayan R, Pocovi T, Tate T, Coussens M, Tofts L, **Munns C**, Pacey V. Development of the Screening Tool for Everyday Mobility and Symptoms (STEMS) for skeletal dysplasia. *Orphanet J Rare Dis*. 2021 Jan 21;16(1):40. doi: 10.1186/s13023-021-01681-z.
9. Simm PJ, **Munns CF**, Jefferies CA, Wheeler BJ. Editorial: Childhood Rickets – New Developments in Epidemiology, Prevention and Treatment. *Front Endocrinol (Lausanne)*. 2020 Nov 23;11:621734.
10. Wesley A, Bray P, **Munns CF**, Pacey V. Impact of heritable disorders of connective tissue on daily life of children: Parent perspective. *J Paediatr Child Health*. 2020 Nov 26, Online ahead of print.
11. Graves LE, Wall CL, Briody JN, Bennetts B, Wong K, Onikul E, Biggin A, **Munns CF**. High Bone Mineral Density Osteogenesis Imperfecta in a Family with a Novel Pathogenic Variant in COL1A2. *Horm Res Paediatr*. 2020;93(4):263-271
12. Kozgar SAM, Chay P, **Munns CF**. Screening of vitamin D and calcium concentrations in neonates of mothers at high risk of vitamin D deficiency. *BMC Pediatr*. 2020 Jul 4;20(1):332

13. Lee SL, Lim A, **Munns C**, Simm PJ, Zacharin M. Effect of Testosterone Therapy for Delayed Puberty in Duchenne Muscular Dystrophy. *Horm Res Paediatr*. 2020;93(2):108-118
14. Siafarikas A, Simm P, Zacharin M, Jefferies C, Lafferty AR, Wheeler BJ, Tham E, Brown J, Biggin A, Hofman P, Woodhead H, Rodda C, Jensen D, Brookes D, **Munns CF**. APEG Bone and Mineral Working Group. Global consensus on nutritional rickets: Implications for Australia. *J Paediatr Child Health*. 2020 June;56(6):841-846
15. Vesey RM, Hofman PL, Derraik JG, Colle P, Biggs JB, **Munns CF**, Cutfield WS, Gusso S. Safety, feasibility and efficacy of side-altering vibration therapy on bone and muscle health in children and adolescents with musculoskeletal disorders: A pilot study. *J Paediatr Child Health*. 2020 Aug;26(8):1257-1262.
16. Schindeler A, Biggin A, **Munns CF**. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. *Front Endocrinol*. 2020 May 28; 11:338
17. Gusso S, Vesey RM, Derraik JGB, **Munns CF**, Colle P, Biggs JB, Hofman PL. The Effects of 20 Weeks of Side-Alternating Vibration Therapy on Physical Function, Bone and Muscle Health in Adolescents with Down Syndrome. *Phys Occup Ther Pediatr*. 2020 Apr 28:1-12.
18. Chrisp GL, Torpy DJ, Maguire AM, Quartararo M, Falhammar H, King BR, **Munns CF**, Hameed S, Rushworth RL. The effect of patient-managed stress dosing on electrolytes and blood pressure in acute illness in children with adrenal insufficiency. *Clin Endocrinol (Oxf)*. 2020 Aug;93(2):97-103
19. Ward LM, Weber DR, **Munns CF**, Höglér W, Zemel BS. A Contemporary View of the Definition and Diagnosis of Osteoporosis in Children and Adolescents. *J Clin Endocrinol Metab*. 2020 May 1;105(5):e2208-97.
20. Dean B, Chrisp GL, Quartararo M, Maguire AM, Hameed S, King BR, **Munns CF**, Torpy DJ, Falhammar H, Rushworth RL. P450 oxidoreductase deficiency: A systematic review and meta-analysis of genotypes, phenotypes and their relationships. *J Clin Endocrinol Metab*. 2020 Mar 1;105(3).
21. Morse A, McDonald MM, Mikulec K, Schindeler A, **Munns CF**, Little DG. Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model. *Calcif Tissue Int*. 2020 Feb;106(2):172-179.
22. Tannous P, Fiscoletti M, Wood N, Gunasekera H, Zurynski Y, Biggin A, Kilo T, Hayes E, **Munns C**. Safety and effectiveness of stoss therapy in children with vitamin D deficiency. *J Paediatr Child Health*. 2020 Jan;56(1):81-89.
23. Wheeler BJ, Snoddy AME, **Munns C**, Simm P, Siafarikas A, Jefferies C. A Brief History of Nutritional Rickets. *Front Endocrinol (Lausanne)*. 2019 Nov 14;10:795. eCollection 2019. Review.
24. Lee LR, Peacock L, Lisowski L, Little DG, **Munns CF**, Schindeler A. Targeting Adeno-Associated Virus Vectors for Local Delivery to Fractures and Systemic Delivery to the Skeleton. *Mol Ther Methods Clin Dev*. 2019 Sep 5;15:101-111.
25. Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, **Munns CF**, Lazaretti-Castro M, Giustina A, Bilezikian J. Skeletal and extra-skeletal actions of vitamin D: Current evidence and outstanding questions. *Endocr Rev*. 2019 Aug 1;40(4):1109-1151.
26. Pham-Short A, Donaghue KC, Ambler G, Briody J, Garnett S, **Munns CF**, Craig ME. Abnormal Cortical and Trabecular Bone in Youth With Type 1 Diabetes and Celiac Disease. *Diabetes Care*. 2019 Aug;42(8):1489-1495.
27. Imel EA, Glorieux FH, Whyte MP, **Munns CF**, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Höglér W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional

- therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. *Lancet*, 2019 Jun 15;393(10189):2416-2427.
28. Imel EA, Biggin A, Schindeler A, **Munns CF**. FGF23, Hypophosphatemia, and Emerging Treatments. *JBMR Plus*, 2019. May 13;3(8):e10190.
 29. Lee LR, Peacock L, Ginn SL, Cantrill LC, Cheng TL, Little DG, **Munns CF**, Schindeler A. Bone Marrow Transplantation for Treatment of the Col1a2+/G610C Osteogenesis Imperfecta Mouse Model. *Calcif Tissue Int*. 2019 Apr;104(4):426-436.
 30. Mumford J, Kohn M, Briody J, Miskovic-Wheatley J, Madden S, Clarke S, Biggin A, Schindeler A, **Munns C**. Long-term Outcomes of Adolescent Anorexia Nervosa on Bone. *J Adolesc Health*. 2019 Mar;64(3):305-310
 31. Jamil K, Walker T, Onikul E, **Munns CF**, Little DG. A comparison of subtraction MRI with the standard contrast-enhanced imaging in Perthes' disease. *J Child Orthop*. 2019 Feb 1;13(1):82-88.
 32. Offiah AC, Vockley J, **Munns CF**, Murotsuki J. Differential diagnosis of perinatal hypophosphatasia: radiologic perspectives. *Pediatric Radiology*. 2019 Jan;49(1):3-22.
 33. Kwan B, Champion B, Boyages S, **Munns CF**, Clifton-Bligh R, Luxford C, Crawford B. A novel CASR mutation (p.Glu757Lys) causing autosomal dominant hypocalcaemia type 1 *Endocrinol Diabetes Metab Case Rep*. 2018 Sep 25;2018
 34. Chrisp GL, Maguire AM, Quartararo M, Falhammar H, King BR, **Munns CF**, Torpy DJ, Hameed S, Rushworth RL. Variations in the management of acute illness in children with congenital adrenal hyperplasia: An audit of three paediatric hospitals. *Clin Endocrinol (Oxf)*. 2018 Nov;89(5):577-585.
 35. Fisaletti M, Coorey CP, Biggin A, Briody J, Little DG, Schindeler A, **Munns CF**. Diagnosis of Recurrent Fracture in a Pediatric Cohort. *Calcif Tissue Int*. 2018 Nov;103(5):529-539.
 36. Ebeling P, Adler R, Jones G, Liberman UA, Mazziotti G, Minisola S, **Munns C**, Napoli N, Pittas A, Giustina A, Bilezikian JP, Rizzoli R. Management of Endocrine Disease: Therapeutics of Vitamin D. *Eur J Endocrinol*. 2018 Oct 12;179(5):R239-R259
 37. Sempos CT, Heijboer AC, Bikle DD, Bollerslev J, Bouillon R, Brannon PM, DeLuca HF, Jones G, **Munns CF**, Bilezikian JP, Giustina A, Binkley N. Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. *Br J Clin Pharmacol*. 2018 Oct;84(10):2194-2207.
 38. Fisaletti M, Biggin A, Bennetts B, Wong K, Briody J, Pacey V, Birman C, **Munns CF**. Novel variant in Sp7/Osx associated with recessive osteogenesis imperfecta with bone fragility and hearing impairment. *Bone*. 2018 May;110:66-75.
 39. Simm PJ, Biggins A, Zacharin MR, Roda CP, Tham E, Siafarikas A, Jefferies A, Hofman PL, Jensen DE, Woodhead H, Brown J, Wheeler BJ, Brookes D, Lafferty A, **Munns CF**. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. *J Paed Child Health*. 2018 Mar;54(3):223-233.
 40. Jamil K, Zacharin M, Foster B, Donald G, Hassall T, Siafarikas A, Johnson M, Tham E, Whitewood C, Gebiski V, Cowell CT, Little DG, **Munns CF**. Protocol for a randomised control trial of bisphosphonate (zoledronic acid) treatment in childhood femoral head avascular necrosis due to Perthes disease. *BMJ Paediatr Open*. 2017 Sep 14;1(1):e000084.
 41. Fisaletti M, Stewart P, **Munns CF**. The importance of vitamin D in maternal and child health: a global perspective. The importance of vitamin D in

- maternal and child health: a global perspective. *Public Health Reviews*. 2017 Sep 1; 38:19.
42. Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, **Munns CF**, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. *Mol Genet Metab*. 2017 Sep;122(1-2):4-17.
 43. Biggin A, **Munns CF**. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta. *Curr Osteoporos Rep*. 2017 Aug 19.
 44. Little DG, Peacock L, Mikulec K, Kneissel M, Kramer I, Cheng TL, Schindeler A, **Munns C**. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta. *Bone*. 2017 Aug;101:96-103.
 45. Mughal MZ, Thacker TD, Specker BL, Shaw NJ, Kiely M, **Munns CF**, Hogler W. Response to the letter by Sugiyama and Oda. *J Clin Endocrinol Metab*. 2016 Oct;101(10):L97-L98.
 46. Thacher TD, Pludowski P, Shaw NJ, Mughal MZ, **Munns CF**, Hogler W. Nutritional rickets in immigrant and refugee children. *Public Health Reviews*. 2016;37(1):Article 3.
 47. Wong MT, van Ravenswaaij-Arts CM, **Munns CF**, Hsu P, Mehr S, Bocca G. J Central Adrenal Insufficiency is Not a Common Feature in CHARGE Syndrome: A Cross-Sectional Study in 2 Cohorts. *Pediatr*. 2016 Sep;176:150-5.
 48. Hogler W, **Munns CF**. Rickets and osteomalacia: a call for action to protect immigrants and ethnic risk groups. *Lancet Glob Health*. 2016 Apr;4(4):e229-30.
 49. Bishop N, **Munns CF**, Ozono K. Transformative therapy in hypophosphatasia. *Arch Dis Child*. 2016 Jun;101(6):514-5.
 50. Gusso S, **Munns CF**, Colle P, Derraik JG, Biggs JB, Cutfield WS, Hofman PL. Effects of whole-body vibration on physical function, bone and muscle mass in adolescents and young adults with cerebral palsy. *Sci Rep*. 2016 Mar 3;6:22518.
 51. **Munns CF**, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, Michigami T, Tiosano D, Mughal MZ, Mäkitie O, Ramos-Abad L, Ward L, DiMeglio LA, Atapattu N, Cassinelli H, Braegger C, Pettifor JM, Seth A, Wasagu Idris H, Bhatia V, Fu J, Goldberg G, Sävendahl L, Khadgawat R, Pludowski P, Maddock J, Hyppönen E, Oduwole A, Frew E, Aguiar M, Tulchinsky T, Butler G, Högl W. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. *J Clin Endocrinol Metab*. 2016 Feb;101(2):394-415.
 52. **Munns CF**, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, Michigami T, Tiosano D, Mughal MZ, Mäkitie O, Ramos-Abad L, Ward L, DiMeglio LA, Atapattu N, Cassinelli H, Braegger C, Pettifor JM, Seth A, Wasagu Idris H, Bhatia V, Fu J, Goldberg G, Sävendahl L, Khadgawat R, Pludowski P, Maddock J, Hyppönen E, Oduwole A, Frew E, Aguiar M, Tulchinsky T, Butler G, Högl W. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. *Horm Res Paediatr*. 2016;85(2):83-106.
 53. Jefferson A, Leonard H, Siafarikas A, Woodhead H, Fyfe S, Ward LM, **Munns C**, Motil K, Tarquinio D, Shapiro JR, Brismar T, Ben-Zeev B, Bisgaard AM, Coppola G, Ellaway C, Freilinger M, Geerts S, Humphreys P, Jones M, Lane J, Larsson G, Lotan M, Percy A, Pineda M, Skinner S, Syhler B, Thompson S, Weiss B, Witt Engerström I, Downs J. Clinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available Evidence. *PLoS One*. 2016 Feb 5;11(2):e0146824.

54. Padhye B, Dalla-Pozza L, Little D, **Munns C**. Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL). *Cancer Med*. 2016 May;5(5):960-7.
55. Rushworth RL, Falhammar H, **Munns CF**, Maguire AM, Torpy DJ. Hospital Admission Patterns in Children with CAH: Admission Rates and Adrenal Crises Decline with Age. *Int J Endocrinol*. 2016;2016 5748264.
56. Hsu P, Ma A, Barnes EH, Wilson M, Hoefsloot LH, Rinne T, **Munns C**, Williams G, Wong M, Mehr S. The Immune Phenotype of Patients with CHARGE Syndrome. *J Allergy Clin Immunol Pract*. 2015 Nov 7.
57. Titmus AT, Biggin A, Korula S, **Munns CF**. Diagnosis and Management of Osteoporosis in Children. *Curr Pediatr Rep*. 2015 3:187-199.
58. Korula S, Titmuss AT, Biggin A, **Munns CF**. A Practical Approach to Children with Recurrent Fractures. *Endocr Dev*. 2015;28:210-25.
59. Hsu P, Ma A, Barnes EH, Wilson M, Hoefsloot LH, Rinne T, **Munns C**, Williams G, Wong M, Mehr S. The Immune Phenotype of Patients with CHARGE Syndrome. *J Allergy Clin Immunol Pract*. 2015 Nov 7.
60. **Munns CF**, Fahiminiya S, Poudel N, Munteanu MC, Majewski J, Sillence DO, Metcalf JP, Biggin A, Glorieux F, Fassier F, Rauch F, Hinsdale ME. Homozygosity for Frameshift Mutations in XYLT2 Result in a Spondylo-Ocular Syndrome with Bone Fragility, Cataracts, and Hearing Defects. *Am J Hum Genet*. 2015 Jun 4;96(6):971-8
61. Brookes DS, Briody JN, **Munns CF**, Davies PS, Hill RJ. Cystic fibrosis-related bone disease in children: Examination of peripheral quantitative computed tomography (pQCT) data. *J Cyst Fibros*. 2015 May 6.
62. Pacey V, Adams RD, Tofts L, **Munns CF**, Nicholson LL. Joint hypermobility syndrome subclassification in paediatrics: s factor analysis approach. *Arch Dis Child*. 2015 Jan;100(1):8-13
63. Brookes DS, Briody JN, **Munns CF**, Davies PS, Hill RJ. Cystic fibrosis-related bone disease explored using a four step algorithm. *J Cyst Fibros*. 2015 Jan;14(1):127-34
64. Biggin A, Zheng L, Briody JN, Coorey CP, **Munns CF**. The Long-Term Effects of Switching from Active Intravenous Bisphosphonate Treatment to Low-Dose Maintenance Therapy in Children with Osteogenesis Imperfecta. *Horm Res Paediatr*. 2015 Feb 10.
65. Pacey V, Tofts L, Adams RD, **Munns CF**, Nicholson LL. Quality of life prediction in children with joint hypermobility syndrome. *J Paediatr Child Health*. 2015 Jan 26.
66. Bhatt R, Hibbert S, **Munns C**. Use of bisphosphonates in children: authors' reply. *Aust Dent J*. 2014 Sep;59(3):405-6.
67. Pacey V, Adams RD, Tofts L, **Munns CF**, Nicholson LL. Proprioceptive acuity into knee hypermobile range in children with joint hypermobility syndrome. *Pediatr Rheumatol Online J*. 2014 Sep 8;12:40.
68. Brookes DS, Briody JN, **Munns CF**, Davis PS, Hill RJ. Cystic fibrosis-related bone disease explored using a four step algorithm. *J Cyst Fibros*. 2014 Aug 26.
69. Cheng A, Sambrook P, Goss A, Bhatt R, Hibbert S, **Munns C**. Letters to the editor. *Aust Dent J*. 2014 Sept;59(3):405-6.
70. Biggin A, **Munns CF**. Osteogenesis Imperfecta: Diagnosis and Treatment. *Curr Osteoporos Rep*. 2014 June 26.
71. Pacey V, Adams RD, Tofts L, **Munns CF**, Nicholson LL. Joint hypermobility syndrome subclassification in paediatrics: a factor analytic approach. *Arch Dis Child*. 2014 May 26.
72. Hsu P, Ma A, Wilson M, Williams G, Curotta J, **Munns CF**, Mehr S. CHARGE syndrome: A review. *J Paediatr Child Health*. 2014 Jul;50(7):504-511.

73. Yap C, Cheung NW, Gunton JE, Athayde N, **Munns CF**, Duke A, McLean M. Vitamin D Supplementation and the Effects on Glucose Metabolism During Pregnancy: A Randomized Controlled Trial. *Diabetes Care*. 2014 Apr 23.
74. Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, Schlingmann KP, Janner M, Biggin A, Lazier J, Gessner M, Chrysis D, Tuchman S, Baluarte HJ, Levine MA, Tiosano D, Insogna K, Hanley DA, Carpenter TO, Ichikawa S, Hoppe B, Konrad M, Säwendahl L, **Munns CF**, Lee H, Jüppner H, Bergwitz C. Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. *J Am Soc Nephrol*. 2014 Apr 3
75. Lazarus S, McInerney-Leo AM, McKenzie FA, Baynam G, Broley S, Cavan BV, **Munns CF**, Pruijs JE, Sillence D, Terhal PA, Pryce K, Brown MA, Zankl A, Thomas G, Duncan EL. The IFITM5 mutation c.-14C > T results in an elongated transcript expressed in human bone; and causes varying phenotypic severity of osteogenesis imperfecta type V. *BMC Musculoskelet Disord*. 2014 Mar 27;15:107.
76. Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, **Munns CF**, Shaw N. Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD 2013 Pediatric Official Positions. *J Clin Densitom*. 2014 Apr-Jun;17(2):275-80
77. Bönnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreira A, Muntoni F, Sewry C, Bérout C, Mathews KD, Moore SA, Bellini J, Rutkowski A, North KN; Members of International Standard of Care Committee for Congenital Muscular Dystrophies. Diagnostic approach to the congenital muscular dystrophies. *Neuromuscul Disord*. 2014 Apr;24(4):289-311
78. North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, Amburgey K, Quijano-Roy S, Beggs AH, Sewry C, Laing NG, Bönnemann CG; International Standard of Care Committee for Congenital Myopathies. Approach to the diagnosis of congenital myopathies. *Neuromuscul Disord*. 2014 Feb;24(2):97-116.
79. Bhatt R, Hibbert S, **Munns CF**. The use of bisphosphonates in children: review of the literature and guidelines for dental management. *Aust Dent J*. 2014 Feb 4
80. Nicholson L, Pacey V, Tofts L, **Munns C**, Adams R. Signs and symptoms of foot and ankle dysfunction in children with joint hypermobility. *Journal of Foot and Ankle Research*. 2014, 7(Suppl1).
81. Biggin A, Briody JN, Ormshaw E, Wong KK, Bennetts BH, **Munns CF**. Fracture during Intravenous Bisphosphonate Treatment in a Child with Osteogenesis Imperfecta: An Argument for a More Frequent, Low-Dose Treatment Regimen. *Horm Res Paediatr*. 2014, 81(3): 204-210
82. Ooi HL, Briody J, Biggin A, Cowell CT, **Munns CF**. Intravenous Zoledronic Acid Given Every 6 Months in Childhood Osteoporosis. *Horm Res Paediatr*. 2013 Sep 17:179-184.
83. Pacey V, Tofts L, Adams RD, **Munns CF**, Nicholson LL. Exercise in children with joint hypermobility syndrome and knee pain: a randomised controlled trial comparing exercise into hypermobile versus neutral knee extension. *Pediatr Rheumatol Online J*. 2013 Aug 14;11(1):30.
84. Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszú E, Lane JM, Lorenc R, Makitie O, **Munns CF**, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013 Oct 26;382(9902):1424-32.
85. Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, Engelbert RH, Sillence DO, **Munns CF**. Intravenous Pamidronate Treatment in Children with

- Moderate-to-Severe Osteogenesis Imperfecta Started under Three Years of Age. *Horm Res Paediatr*. 2013 May 31.
86. Pacey V, Tofts L, Adams R, **Munns CF**, Nicholson L. Exercise in children with Joint Hypermobility Syndrome and knee pain: A randomised controlled trial comparing exercise into hypermobile versus neutral knee extension. *Pediatric Rheumatology*. 2013 Aug 14;11(1):30.
 87. O'Keefe K, Orr R, Huang P, Selvadurai H, Cooper P, **Munns CF**, Singh MA. The effect of whole body vibration exposure on muscle function in children with cystic fibrosis: a pilot efficiency trial. *J Clin Med Res*. 2013 Jun;5(3):205-16.
 88. Padhye B, Dalla-Pozza L, Little DG, **Munns CF**. Use of Zoledronic Acid for Treatment of Chemotherapy Related Osteonecrosis in Children and Adolescents; A Retrospective Study. *Pediatr Blood Cancer*. 2013 Apr 26
 89. Biggin A, Briody JN, Ramjan KA, Middleton A, Waugh MC, **Munns CF**. Evaluation of bone mineral density and morphology using pQCT in children after spinal cord injury. *Dev Neurorehabil*. 2013 Mar 11.
 90. Paxton GA, Teale GR, Nowson CA, Mason RS, McGrath JJ, Thompson MJ, Siafarikas A, Rodda CP, **Munns CF**. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement.; Australian and New Zealand Bone and Mineral Society; Osteoporosis Australia. *Med J Aust*. 2013 Feb 18;198(3):142-3.
 91. Rana M, **Munns CF**, Selvadurai H, Briody J, Craig ME. The impact of dysglycaemia on bone mineral accrual in young people with cystic fibrosis. *Clin Endocrinol (Oxf)*. 2013 Jan;78(1):36-42.
 92. **Munns CF**, Simm PJ, Rodda CP, Garnett SP, Zacharin MR, Ward LM, Geddes J, Cherian S, Zurynski Y, Cowell CT; on behalf of the APSU Vitamin D Study Group. Incidence of vitamin D deficiency rickets among Australian children: an Australian Paediatric Surveillance Unit study. *Med J Aust*. 2012 Apr 16;196(7):466-468.
 93. Ooi HL, Briody J, McQuade M, **Munns CF**. Zoledronic acid improves bone mineral density in pediatric spinal cord injury. *J Bone Miner Res*. 2012 Jul;27(7):1536-40.
 94. Wang CH, Dowling JJ, North K, Schroth MK, Sejersen T, Shapiro F, Bellini J, Weiss H, Guillet M, Amburgey K, Apkon S, Bertini E, Bonnemant C, Clarke N, Connolly AM, Estournet-Mathiaud B, Fitzgerald D, Florence JM, Gee R, Gurgel-Giannetti J, Glanzman AM, Hofmeister B, Jungbluth H, Koumbourlis AC, Laing NG, Main M, Morrison LA, **Munns C**, Rose K, Schuler PM, Sewry C, Storhaug K, Vainzof M, Yuan N. Consensus statement on standard of care for congenital myopathies. *J Child Neurol*. 2012 Mar;27(3):363-82.
 95. Cho YH, Tchan M, Roy B, Halliday R, Wilson M, Dutt S, Siew S, **Munns C**, Howard N. Recombinant parathyroid hormone therapy for severe neonatal hypoparathyroidism. *J Pediatr*. 2012 Feb;160(2):345-8.
 96. Joseph PD, Hemmens VJ, **Munns CF**. Stability of Oral Cholecalciferol (Vitamin D3) Liquid Formulations in Olive Oil. *Journal of Pharmacy Practice and Research*. 2012;42(3):213-217.
 97. Simm PJ, Johannesen J, Briody J, McQuade M, Hsu B, Bridge C, Little DG, Cowell CT, **Munns CF**. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. *Bone*. 2011 Nov;49(5):939-43.
 98. Isaacs D, Tobin B, Hamblin J, Slaytor E, Donaghue KC, **Munns C**, Kilham HA. Managing ethically questionable parental requests: growth suppression and manipulation of puberty. *J Paediatr Child Health*. 2011 Sep;47(9):581-4.
 99. Rana M, **Munns CF**, Selvadurai HC, Simonds S, Cooper PJ, Woodhead HJ, Hameed S, Verge CF, Lafferty AR, Crock PA, Craig ME. Increased detection

- of cystic-fibrosis-related diabetes in Australia. *Arch Dis Child*. 2011 Sep;96(9):823-6.
100. Bridge P, Pocock NA, Nguyen T, **Munns C**, Cowell CT, Forwood N, Thompson MW. Validation of longitudinal DXA changes in body composition from pre- to mid-adolescence using MRI as reference. *J Clin Densitom*. 2011 Jul-Sep;14(3):340-7.
 101. Birke O, Schindeler A, Ramachandran M, Cowell CT, **Munns CF**, Bellemore M, Little DG. Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia. *J Child Orthop*. 2010 Dec;4(6):507-17.
 102. Simm PJ, Briody J, McQuade M, **Munns CF**. The successful use of pamidronate in an 11-year-old girl with complex regional pain syndrome: response to treatment demonstrated by serial peripheral quantitative computerised tomographic scans. *Bone*. 2010 Apr;46(4):885-8.
 103. Rana M, **Munns CF**, Selvadurai H, Donaghue KC, Craig ME. Cystic fibrosis-related diabetes in children--gaps in the evidence? *Nat Rev Endocrinol*. 2010 Jul;6(7):371-8.
 104. Pacey V, Nicholson LL, Adams RD, Munn J, **Munns CF**. Generalized joint hypermobility and risk of lower limb joint injury during sport: a systematic review with meta-analysis. *Am J Sports Med*. 2010 Jul;38(7):1487-97.
 105. David-Vizcarra G, Briody J, Ault J, Fietz M, Fletcher J, Savarirayan R, et al. The natural history and osteodystrophy of mucopolidosis types II and III. *J Paediatr Child Health*. 2010 Jun;46(6):316-22.
 106. Tofts LJ, Elliott EJ, **Munns C**, Pacey V, Sillence DO. The differential diagnosis of children with joint hypermobility: a review of the literature. *Pediatr Rheumatol Online J*. 2009;7:1.
 107. Rauch F, **Munns CF**, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. *J Bone Miner Res*. 2009 Jul;24(7):1282-9.
 108. Ramjan KA, Roscioli T, Rutsch F, Sillence D, **Munns CF**. Generalized arterial calcification of infancy: treatment with bisphosphonates. *Nat Clin Pract Endocrinol Metab*. 2009 Mar;5(3):167-72.
 109. Johannesen J, Briody J, McQuade M, Little DG, Cowell CT, **Munns CF**. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease. *Bone*. 2009 Nov;45(5):898-902.
 110. Cross SF, Dalla Pozza L, **Munns CF**. Hypercalcemia and osteoblastic lesions induced by 13-Cis-retinoic acid mimicking relapsed neuroblastoma. *Pediatr Blood Cancer*. 2009 Oct;53(4):666-8.
 111. Bridge P, Pocock NA, Nguyen T, **Munns C**, Cowell CT, Thompson MW. Prediction of appendicular skeletal and fat mass in children: excellent concordance of dual-energy X-ray absorptiometry and magnetic resonance imaging. *J Pediatr Endocrinol Metab*. 2009 Sep;22(9):795-804.
 112. Benitez-Aguirre PZ, Wood NJ, Biesheuvel C, Moreira C, **Munns CF**. The natural history of vitamin D deficiency in African refugees living in Sydney. *Med J Aust*. 2009 Apr 20;190(8):426-8.
 113. Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, **Munns C**, Wenket D, Zeitler P. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. *J Clin Densitom*. 2008 Jan-Mar;11(1):22-8.
 114. Liu AJ, Briody JN, **Munns CF**, Waugh MC. Regional changes in bone mineral density following spinal cord injury in children. *Dev Neurorehabil*. 2008 Jan-Mar;11(1):51-9.
 115. Gleeson H, Wiltshire E, Briody J, Hall J, Chaitow J, Sillence D, Little DG, Cowell, CT, **Munns CF**. Childhood chronic recurrent multifocal osteomyelitis:

- pamidronate therapy decreases pain and improves vertebral shape. *J Rheumatol*. 2008 Apr;35(4):707-12.
116. Ramachandran M, Ward K, Brown RR, **Munns CF**, Cowell CT, Little DG. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. *J Bone Joint Surg Am*. 2007 Aug;89(8):1727-34.
 117. **Munns CF**, Rajab MH, Hong J, Briody J, Hogler W, McQuade M, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. *Bone*. 2007 Sep;41(3):366-70.
 118. Bellemore, M., **Munns, C**. Osteogenesis Imperfecta. *Locomotor System: Advances in Research, Diagnostics and Therapy*, 2007. 14(3+4), 232-238.
 119. Zeitlin L, Rauch F, Travers R, **Munns C**, Glorieux FH. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. *Bone*. 2006 Jan;38(1):13-20.
 120. Rauch F, **Munns C**, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. *J Clin Endocrinol Metab*. 2006 Apr;91(4):1268-74.
 121. **Munns C**, Zacharin MR, Rodda CP, Batch JA, Morley R, Cranswick NE, et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. *Med J Aust*. 2006 Sep 4;185(5):268-72.
 122. Land C, Rauch F, **Munns CF**, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. *Bone*. 2006 Oct;39(4):901-6.
 123. **Munns CF**, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. *J Bone Miner Res*. 2005 Jul;20(7):1235-43.
 124. **Munns CF**, Cowell CT. Prevention and treatment of osteoporosis in chronically ill children. *J Musculoskelet Neuronal Interact*. 2005 Jul-Sep;5(3):262-72.
 125. Rauch F, Travers R, **Munns C**, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. *J Bone Miner Res*. 2004 Jul;19(7):1191-3.
 126. **Munns CF**, Haase HR, Crowther LM, Hayes MT, Blaschke R, Rappold G, et al. Expression of SHOX in human fetal and childhood growth plate. *J Clin Endocrinol Metab*. 2004 Aug;89(8):4130-5.
 127. **Munns CF**, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. *J Bone Miner Res*. 2004 Nov;19(11):1779-86.
 128. **Munns CF**, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. *J Bone Miner Res*. 2004 Oct;19(10):1742-5.
 129. **Munns CF**, Rauch F, Travers R, Glorieux FH. Three children with lower limb fractures and a mineralization defect: a novel bone fragility disorder? *Bone*. 2004 Nov;35(5):1023-8.
 130. **Munns CF**, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. *Bone*. 2004 Jul;35(1):231-4.
 131. Plotkin H, Rauch F, Zeitlin L, **Munns C**, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. *J Clin Endocrinol Metab*. 2003 Oct;88(10):4569-75.
 132. **Munns CF**, Glass IA, Flanagan S, Hayes M, Williams B, Berry M, et al. Familial growth and skeletal features associated with SHOX haploinsufficiency. *J Pediatr Endocrinol Metab*. 2003 Sep;16(7):987-96.
 133. **Munns CF**, Berry M, Vickers D, Rappold GA, Hyland VJ, Glass IA, et al. Effect of 24 months of recombinant growth hormone on height and body

- proportions in SHOX haploinsufficiency. *J Pediatr Endocrinol Metab.* 2003 Sep;16(7):997-100.
134. Flanagan SF, **Munns CF**, Hayes M, Williams B, Berry M, Vickers D, et al. Prevalence of mutations in the short stature homeobox containing gene (SHOX) in Madelung deformity of childhood. *J Med Genet.* 2002 Oct;39(10):758-63.
135. **Munns CF**, Glass IA, LaBrom R, Hayes M, Flanagan S, Berry M, et al. Histopathological analysis of Leri-Weill dyschondrosteosis: disordered growth plate. *Hand Surg.* 2001 Jul;6(1):13-23.
136. **Munns CF**, Batch JA. Hyperinsulinism and Beckwith-Wiedemann syndrome. *Arch Dis Child Fetal Neonatal Ed.* 2001 Jan;84(1):F67-9.
137. Healey SC, Kirk KM, Hyland VJ, **Munns CF**, Henders AK, Batch JA, et al. Height discordance in monozygotic females is not attributable to discordant inactivation of X-linked stature determining genes. *Twin Res.* 2001 Feb;4(1):19-24.
138. **Munns CF**, McCrossin RB, Thomsett MJ, Batch J. Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes. *J Paediatr Child Health.* 2000 Oct;36(5):449-52.

(ii) Book Chapters

1. **Munns CF.** Avascular (Aseptic) Necrosis of the Femoral Head (Hip). In: The 5-Minute Pediatric Consult Standard 7th Edition. 2015
2. Korula S, Titmuss AT, Biggin A, **Munns CF.** A Practice Approach to Children with Recurrent Fractures. In: Calcium and Bone Disorders in Children and Adolescents. 2015.
3. Biggin A, **Munns CF.** Bisphosphonates in Osteogenesis Imperfecta. In: Bone Drugs in Pediatrics. 2014.
4. Hallett, KB, Alexander S, Wilson M, **Munns CF,** Cameron AC, Widmer RP. Medically compromised children. In: Handbook of Pediatric Dentistry 4th Edition. 2013.
5. **Munns CF.** Adolescent Bone Health. In: A Clinical Handbook in Adolescent Medicine. 2013.
6. **Munns CF,** Boot A. Bone Health. In: Practice Paediatric Endocrinology in a Limited Resource Setting. 2013.
7. **Munns CF,** Glorieux FH. Medical therapy in Osteogenesis Imperfecta. In: Multidisciplinary Treatment Approach for Children with Osteogenesis Imperfecta. 2004
8. Co-editor. Multidisciplinary Treatment Approach for Children with Osteogenesis Imperfecta. 2004
9. **Munns CF,** Sillence DO. Disorders Predisposing to Bone Fragility and Decreased Bone Density. Emery and Rimoin's Principles and Practice of Medical Genetics. Fifth Edition. 2006
10. Sillence DO, **Munns CF.** Disorders with Increased Bone Density, Volume and Mineralization. Emery and Rimoin's Principles and Practice of Medical Genetics. Fifth Edition. 2006
11. **Munns CF,** Glass IA. SHOX(Y)-Haploinsufficiency Disorders. in: /GeneReviews /at GeneTests: Medical Genetics Information Resource [database online]. 2005 (updated 2012)

(iii) Peer Reviewed Presentations

1. **Munns C**, Morris A, Simm P, Biggin A, Elliott E. X-linked Hypophosphataemic Rickets. RACP Annual Scientific Meeting. May 2021.
2. Little D, Jamil K, **Munns C**, Cowell C, Foster B, Johnson M, Donald G, Whitehead C. A Randomized Controlled Trail of Zoledronic Acid in Perthes Disease (ZAP). Pediatric Orthopedic Society of North America, Annual Scientific Meeting. Charlotte, USA, May 2019.
3. **Munns C**, Jamil K, Cowell C, Foster B, Johnson M, Donald G, Whitehead C, Little D. Bisphosphonate improves hip range of motion and pain but not femoral head sphericity. A multicentre, randomized clinical trail of children with Perthes Disease. APEG Annual Scientific Meeting. Adelaide. September 2019.
4. Imel EA, Whyte MP, **Munns C**, et al. Burosumab Resulted in Greater Improvement in Rickets than Conventional Therapy in Children with X-linked Hypophosphatemia (XLH). In. Vol March 23-26, 2019. Endocrine Society Annual Meeting (ENDO) New Orleans, LA; 2019. [Oral].
5. Jamil K, Little DL, **Munns CF**. The effects of intravenous zoledronic acid in children with Perthes Disease; clinical, quality of life and safety data after 1 year. 20th Asia Pacific Orthopaedic Association Congress. Antalya, Turkey, 10-14th April 2018.
6. Imel EA, Whyte MP, **Munns C**, et al. Burosumab Improved Rickets, Phosphate Metabolism, and Clinical Outcomes Compared to Conventional Therapy in Children with XLH. In. Vol September 28 - October 01, 2018. American Society for Bone and Mineral Research (ASBMR): Montreal, QC, Canada; 2018. [Oral].
7. Imel EA, Whyte MP, **Munns C**, et al. Burosumab Improved Rickets, Phosphate Metabolism, and Clinical Outcomes Compared to Conventional Therapy in Children with XLH. Journal of Bone and Mineral Research. 2018;33(S1):S1-S464.
8. Portale AA, Imel E, **Munns C**, et al. Burosumab Improves Rickets and Clinical Outcomes Compared to Conventional Therapy in Children with XLH In. Vol Oct 25 – 28, 2018. Annual American Society of Nephrology (ASN): San Diego, CA; 2018. [Poster].
9. Nilsson O, Whyte MP, Imel EA, et al. Burosumab Improved Rickets, Phosphate Metabolism, and Clinical Outcomes Compared to Conventional Therapy in Children with X-linked hypophosphatemia (XLH) – A Randomized Controlled Phase 3 Study. In. Vol September 27-29, 2018. European Society for Pediatric Endocrinology (ESPE) Athens, Greece; 2018. [Oral].
10. Padidela R, Carpenter TO, Imel E, et al. Burosumab, An Anti-FGF23 Monoclonal Antibody, For X-Linked Hypophosphatemia (XLH): Analysis by Age from Two Phase 2 Pediatric Trials. In. Vol April 19-22, 2018. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease (WCO-IOF): Krakow, Poland; 2018. [Oral and Poster].
11. Little D, Jamil K, **Munns C**, Cowell C, Foster B, Johnson M, Donald G, Whitehead C. A Randomized Controlled Trail of Zoledronic Acid in Perthes Disease (ZAP). Pediatric Orthopedic Society of North America, Annual Scientific Meeting. Charlotte, USA, May 2019.
12. Jamil K, Little DL, **Munns CF**. The effects of intravenous zoledronic acid in children with Perthes Disease; clinical, quality of life and safety data after 1 year. 20th Asia Pacific Orthopaedic Association Congress. Antalya, Turkey, 10-14th April 2018.
13. Pacey V, Tofts L, Nicholson L, Adams R, **Munns C**. Physical Activity of Children with Heritable Disorders of Connective Tissue: A Comparative Study. Australian Physiotherapy Association Biennial Conference Momentum, October 2017.
14. Hutchence M, Pacey V, **Munns C**, North K, Clarke N, Rose K, Biggin A. Whole Body Vibration Training for Children and Adolescents with Congenital Myopathy.

Australian Physiotherapy Association Biennial Conference Momentum, October 2017

15. Jones T, Theophile I, Price A, **Munns C**, Pacey V. Physical Activity Levels and the Perceived Barriers to Physical Activity Participation in Children with Osteogenesis Imperfecta. Australian Physiotherapy Association Biennial Conference Momentum, October 2017.
16. Jones T, Theophile I, Price A, **Munns C**, Pacey V. Physical Activity Levels and the Perceived Barriers to Physical Activity Participation in Children with Osteogenesis Imperfecta. 13th International Conference on Osteogenesis Imperfecta. Oslo, Norway. August 2017
17. Pacey V, Stone H, Mann S, **Munns C**, Biggin A. Prevalence and progression of spondylolistheses in children with Osteogenesis Imperfecta. 13th International Conference on Osteogenesis Imperfecta. Oslo, Norway. August 2017.
18. Jones T, Theophile I, Price A, Chmielewski A, Lozano M, **Munns C**, Pacey V. Barriers Impacting on Participation in Physical Activity for Children with Osteogenesis Imperfecta: A Study of Child and Parent Perspectives. World Confederation for Physical Therapy Congress. New York, USA. July 2017
19. Jamil K, Little DL, **Munns CF**. Randomized Clinical Trial Of Bisphosphonate Treatment In Childhood Femoral Head Avascular Necrosis Due To Perthes Disease: Study Design, Methods And Baseline Data' 47th Malaysian Orthopaedic Association Annual General Meeting/Annual Scientific Meeting, 19-21st May 2017.
20. Jamil K, **Munns CF**, Little DL. Comparison Of Contrast-Enhanced Mri With And Without Subtraction Technique In Perthes Disease APOS Instructional Course & Combined APOS/POSNZ Annual Scientific Meeting, Millennium, Queenstown, New Zealand, 29th August - 2nd September & 3rd - 4th September, 2017.
21. Pacey V, Jones T, Lozano M, Chmielewski A, Price A, Theophile I, **Munns C**. Physical activity of children with Osteogenesis Imperfecta. 1st Asia Pacific Bone Disorders Symposium. September, 2016.
22. Wesley A, **Munns C**, Bray P, Pacey V. Parents and therapists working in partnership: a questionnaire to explore parent perceptions of the impact of a Connective Tissue Dysplasia on their child's daily functioning. 1st Asia Pacific Bone Disorders Symposium. Melbourne, Australia. September, 2016.
23. Theophile I, Pacey V, Price A, Chmielewski A, Lozano M, **Munns C**, Jones T. Barriers impacting on participation in physical activity for children with osteogenesis imperfecta: a cross sectional study of child and parent perspectives. 1st Asia Pacific Bone Disorders Symposium. Melbourne, Australia. September, 2016.
24. Price A, Pacey V, Theophile I, Chmielewski A, Lozano M, **Munns C**, Jones T. Relationship between physical self-efficacy, physical self-concept, and physical activity in children and adolescents with Osteogenesis Imperfecta: a cross-sectional study. 1st Asia Pacific Bone Disorders Symposium. Melbourne, Australia. September, 2016.
25. Biggin A, **Munns CF**, Peacock L, Mikulec K, Kneissel M, Kramer I, Cheng T, Schindeler A, Little DG. Combination Sclerostin Antibody and Zoledronic Acid Treatment Outperforms Either Treatment Alone in a Mouse Model of Osteogenesis Imperfecta. 7th International Conference on Children's Bone Health, Salzburg, Austria. June 2015

26. Pacey V, Nicholson LL, Adams RD, Tofts L, **Munns C**. A randomized controlled trial of two exercise programmes for children with Joint Hypermobility Syndrome and knee pain. Australian Physiotherapy Association 10th Biennial Conference. October, 2013
27. Pacey V, Nicholson LL, Adams RD, Tofts L, **Munns C**. Quality of life, pain and fatigue in Joint Hypermobility Syndrome: A parent and child's perspective (invited speaker). Australian Rheumatology Association 54th Annual Scientific Meeting, Paediatric Satellite Meeting. May 2013
28. Pacey V, Nicholson LL, Adams RD, Tofts L, **Munns C**. The fatigue experience of children with Joint Hypermobility Syndrome: A parent and child's perspective. Australian Rheumatology Association 54th Annual Scientific Meeting. May 2013
29. **Munns CF**. Long-term effects of bisphosphonate therapy in children with osteogenesis imperfecta. 6th International Conference on Children's Bone Health, Rotterdam, Netherlands. June 2013.
30. Biggin A, **Munns CF**. Six monthly intravenous zoledronic acid in childhood osteoporosis. 6th International Conference on Children's Bone Health, Rotterdam, Netherlands. June 2013.
31. Gusso S, **Munns CF**, Hofman P. Short-term whole body vibration therapy improves bone density and muscle function in adolescents with cerebral palsy. Annual Scientific Meeting Australasian Paediatric Endocrine Group. Sydney, Australia. 2013.
32. Zheng L, Biggin A, **Munns CF**. Long-term effects of bisphosphonate therapy in children with osteogenesis imperfecta. Annual Scientific Meeting Australasian Paediatric Endocrine Group. Sydney, Australia. 2013.
33. Robinson A, **Munns CF**, Kristi Jones, Helena Young, Yen Thanh Mac, Sue Ditchfield, Kate Armstrong, Quynh T.V. Huynh, Nguyen Ngoc Khanh, Bui Phuong Thao, Can Thi Bich Ngoc, Vu Chi Dung. Working together so all children can have the chance to walk and run. Annual Scientific Meeting Australasian Paediatric Endocrine Group. Sydney, Australia. 2013.
34. Estrella J, Bakshi M, **Munns CF**, Schwarze U, Cundy T, Sillence D. Moderately-Severe Osteogenesis Imperfecta due to FKBP10 Mutations in Non-Consanguineous Australian Families. Conference: American Society of Human Genetics 2012. San Francisco, USA. November 2012.
35. Middleton A, Selvadurai H, Christodoulou J, **Munns CF**. Whole body vibration training for children with cystic fibrosis. Conference: European Cystic Fibrosis Conference, Dublin, Ireland, June 2012.
36. Pacey V, Nicholson L, Adams R, Munn J, **Munns CF**. Generalised joint hypermobility and risk of lower limb joint injury during sport: A systematic review with meta-analysis. Australian Rheumatology Association 53rd Annual Scientific Meeting, Canberra, Australia. May 2012
37. Pacey V, Tofts L, Adams, R, **Munns CF**, Nicholson L. Exercise Programmes for Children with Joint Hypermobility Syndrome and Knee Pain: A Randomised Controlled Trial. Conference: Australian Rheumatology Association 53rd Annual Scientific Meeting, Canberra, Australia, May 2012.
38. Ooi HL, Briody J, McQuade M, Cowell CT, **Munns CF**. Zoledronic Acid Improves Bone Mineral Density if Paediatric Spinal Cord Injury. Conference: 29th Annual Scientific Meeting Australasian Paediatric Endocrine Group. Perth, Australia. 2011.
39. Ooi HL, Briody J, McQuade M, Cowell CT, **Munns CF**. Six Monthly Intravenous Zoledronic Acid in Childhood Osteoporosis. Conference: 29th Annual Scientific Meeting Australasian Paediatric Endocrine Group. Perth, Australia. 2011.
40. Pacey V, Tofts L, Adams R, Nicholson L, **Munns CF**. Quality of Life in Children with Joint Hypermobility Syndrome. Australian Physiotherapy Association 9th Biennial Conference, Brisbane, October 2011

41. Ramjan KA, Broderick C, Van Doorn N, Briody JN, Garnett SP, Winning K, Lawrie E, Burrell S, Chisholm K, Baur L, **Munns CF**, Cowell CT. Effect of Whole Body Vibration Training on Insulin Sensitivity in Overweight Adolescents: A Randomised Control Trial. Diabetes Symposia RNS/ Kolling Institute/ USYD/UTS scientific meeting. 2011.
42. Rana M, **Munns C**, Selvaduria H, Cooper P, Craig M. The Impact of Dysglycaemia on Bone Mineral Density in Young Cystic Fibrosis Patients 9th Australasian Cystic Fibrosis Conference, Melbourne Victoria, August 2011.
43. Ramjan KA, Broderick CR, Briody JN, Van Dooran N, Barzi F, Winning K, Lawrie E, Garnett SP, Burrell S, Chisholm K, Baur LA, **Munns CF**, Cowell CT. The Effect of Whole Body Vibration Training on Insulin Sensitivity in Overweight Adolescents: A Randomised Control Trial. Conference: ENDO 2011. Boston, USA. June 2011.
44. Simm PJ, Briody J, Schindler A, Cowell CT, Little D, North K, **Munns CF**. Bone Health in Children with Neurofibromatosis Type 1 – A High Incidence of abnormal Vertebral Morphometry, Impaired Muscle Function and altered Skeletal Geometry. Conference: 6th Black Forrest Forum for Musculoskeletal Interactions. Germany. May 2011.
45. Rana M, Simonds S, Selvaduria H, Cooper P, Crock P, Lafferty T, Hameed S, Verge C, **Munns C**, Craig M. Population-based Incidence and Prevalence of CFRD in NSW and ACT. Conference: 70th American Diabetes Association Scientific Sessions, Orlando Florida, June 2010.
46. Ramjan KA, Broderick C, Van Doorn N, Briody JN, Garnett SP, Winning K, Lawrie E, Burrell S, Chisholm K, Baur L, **Munns CF**, Cowell CT. Cardio-respiratory fitness is related to fatness, insulin sensitivity and body composition in overweight insulin resistant adolescents. APEG ASM Adelaide, SA, Australia. 2010.
47. Birke O, Schindeler A, Ramachandran M, Peacock L, Mikulec K, Morse A, Yu N, Baldock P, Cowell C, **Munns C**, Bellemore M, Little DG. Treatment of congenital pseudarthrosis of the tibia using recombinant bone morphogenetic protein and bisphosphonates. Conference: IBMS Davos Workshops: Bone Biology and Therapeutics, Davos, Switzerland, 2010.
48. Rana M, Simonds S, Selvaduria H, Cooper P, Crock P, Lafferty T, Hameed S, Verge C, **Munns C**, Craig M. Incidence and Prevalence of CFRD in NSW and ACT. Conference: 27th Annual Scientific Meeting Australasian Paediatric Endocrine Group. Coolum, Australia. 2009.
49. Alcausin M, Ault J, Pacey V, Briody J, McQuade M, Sillence D & **Munns CF**. The effects of early intravenous pamidronate therapy on gross motor function and fracture frequency in children with osteogenesis imperfecta. Conference: Australian Physiotherapy Association 8th Biennial Conference, Sydney, October 2009
50. Rana M, Selvaduria H, **Munns C**, Craig M. Impact of Diabetes and Impaired Glucose Tolerance of Bone Mineral Density in young Cystic Fibrosis Patients. Incidence and Prevalence of CFRD in NSW and ACT. Conference: 27th Annual Scientific Meeting Australasian Paediatric Endocrine Group. Coolum, Australia. 2009.
51. Rana M, Simonds S, Selvaduria H, Cooper P, Crock P, Lafferty T, Hameed S, Verge C, **Munns C**, Craig M. Incidence and Prevalence of CFRD in NSW and ACT. Conference: 8th Australasian Cystic Fibrosis Conference, Brisbane Queensland, August 29 to September 1, 2009

52. Simm P, Johannesen J, Briody J, Little D, Cowell C, **Munns C**. The use of Zoledronic Acid in Children with Osteopenia – A 2 year Study. Conference: 27th Annual Scientific Meeting Australasian Paediatric Endocrine Group. Coolum, Australia. 2009.
53. Ramjan K, Broderick C, Garnett S, Baur L, **Munns C**, Cowell C. Metabolic, Cardiorespiratory and Musculoskeletal in Overweight Insulin Resistant Adolescents. Conference: 27th Annual Scientific Meeting Australasian Paediatric Endocrine Group. Coolum, Australia. 2009.
54. Alcausin M, Ault J, Pacey V, Briody J, McQuade M, Sillence D, **Munns C**. Intravenous Pamidronate Treatment on Children with Moderate to Severe Osteogenesis Imperfecta started less than 36 months of age. Conference: 5th International Conference on Children's Bone Health, Cambridge, United Kingdom. 2009.
55. Alcausin M, Ault J, Pacey V, Briody J, McQuade M, Sillence D, **Munns C**. The effects of early intervention treatment on infants with Moderate to Severe Osteogenesis Imperfecta. Conference: 19th Annual Scientific Meeting Australian and New Zealand Bone and Mineral Society, Sydney, Australia. 2009.
56. David N, Birke O, Dalla Pozza L, Hobson S, **Munns C**, Little DG. Multiple growth arrests after treatment with cis-transretinoic acid for metastatic neuroblastoma. Conference: Australian Paediatric Orthopaedic Society, Gold Coast, Australia. 2009.
57. Ault, J, Pacey V, Alcausin M, **Munns C**, Broley S & Sillence D. A Multidisciplinary Care Programme for Children with Osteogenesis Imperfecta. 10th International Conference on Osteogenesis Imperfecta, Gent, Belgium October 2008.
58. Johannesen J, Briody J, Little D, Cowell C, **Munns C**. Effects of Zoledronic Acid on Bone and Mineral Metabolism in Children with Femoral Head Avascular Necrosis. Conference: APPEs Biennial Scientific Meeting. Seoul, Korea. 2008.
59. Johannesen J, Briody J, Little D, Cowell C, **Munns C**. A 2 years follow-up study of the effects of Zoledronic Acid on Bone and Mineral Metabolism in Children with Osteoporosis. Conference: 18th Annual Scientific Meeting Australian and New Zealand Bone and Mineral Society. Melbourne, Australia. 2008.
60. **Munns C**, Zacharin M, Rodda C, David E, Harris M, Batch J, Pascoe M, Fairchild J, Lafferty A, Whybourne A, Ward L, Morley R, Garnett S, Burgner D, Geddes J, Cherian S, Mahajan D, Zuryski Y, McKay N and Cowell C. Vitamin D Deficiency Rickets In Australian Children: APSU Update. Conference: 18th Annual Scientific Meeting Australian and New Zealand Bone and Mineral Society. Melbourne, Australia. 2008.
61. **Munns C**, Zacharin M, Rodda C, David E, Harris M, Batch J, Pascoe M, Fairchild J, Lafferty A, Whybourne A, Ward L, Morley R, Garnett S, Burgner D, Geddes J, Cherian S, Mahajan D, Zuryski Y, McKay N and Cowell C. Vitamin D Deficiency Rickets In Australian Children: APSU Update. Conference: Royal Australasian College of Physicians ASM. Adelaide, Australia. 2008.
62. Ramjan K, Briody J, Gallego P, Waugh MC, **Munns C**. Evaluation of Regional Bone Mineral Density in Paediatric Patients after Spinal Cord Injury. Conference: 26th APEG Scientific Conference. Canberra, Australia. 2008.
63. McDonald MM, Morse A, Mikulec K, Mai H, **Munns C**, Little DG. Normal endochondral bone healing follows continuous bisphosphonate pre-treatment in a rat closed fracture model. IBMS Davos Workshops: Bone Biology and Therapeutics. Davos, Switzerland, March 2008.

64. **Munns C**, Zacharin M, Rodda C, David E, Harris M, Batch J, Pascoe M, Fairchild J, Lafferty A, Whybourne A, Ward L, Morley R, Garnett S, Burgner D, Geddes J, Cherian S, Mahajan D, Zurynski Y, McKay N and Cowell C. Vitamin D Deficiency Rickets In Australian Children: APSU Update. Conference: 25th APEG Scientific Conference. Broome, Australia. 2007.
65. **Munns C**, Cowell C, North K, Little D. Regional Osteopenia in Paediatric Patients with Neurofibromatosis Type 1. Conference: 25th APEG Scientific Conference. Broome, Australia. 2007.
66. **Munns C**, Briody J, Little D, Cowell C, North K. Regional Bone Mineral Density in Children with Neurofibromatosis Type 1. Conference: 17th Scientific Meeting of the International Bone and Mineral Society Annual Scientific Meeting. Montreal, Canada. June 2007.
67. Cheung M, Rauch F, Cornibert S, **Munns C**, Land C, Glorieux F. Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. Conference: 5th International Conference on Children's Bone Health. Montreal, Canada. June 2007.
68. Sillence D, Roscioli T, **Munns C**. Infantile Arterial Calcification: Successful Treatment with Bisphosphonates. Conference: 5th International Conference on Children's Bone Health. Montreal, Canada. June 2007.
69. Cowell C, Gleeson H, Wilshire E, Grimwood K, Briody J, Hall J, Chaitow J, Sillence D, **Munns C**. Chronic Recurrent Multifocal Osteomyelitis: Effectiveness of Intravenous Pamidronate in Pain Relief and Spinal Involvement. Conference: 5th International Conference on Children's Bone Health. Montreal, Canada. June 2007.
70. Little DG, Ramachandran M, Ward K, Brown RR, **Munns C**, Cowell C. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents: a prospective case series. Pediatric Orthopaedic Society of North America Annual Meeting, Hollywood, Florida, USA, May 2007.
71. McDonald MM, Morse A, Mikulec K, Mai H, Munns C, Little DG. Normal endochondral bone healing follows continuous bisphosphonate pre-treatment in a rat closed model. 17th Scientific Meeting of the International Bone and Mineral Society, Montreal, Canada, June 2007.
72. **Munns C**, Liu A, Briody J, Waugh M-C. Regional Changes in Bone and Muscle Mass in Children following Spinal Cord Injury. Conference: 28th Annual Scientific Meeting of the American Society of Bone and Mineral Research. Philadelphia, USA. September 2006.
73. Bridge P, Cowell CT, **Munns CF**, O'Connor H, Woodhead H, Briody J, Thompson M. Lean Body Mass: More Important than Calcium Intake on Bone Mineral Accretion in Peripubertal Boy and Girl Elite Athletes. A 3-year Longitudinal Study. Conference: 2006 Joint Meeting of the 3rd International Osteoporosis Foundation Asia-Pacific Regional Conference on Osteoporosis and 16th Annual Meeting of the Australian and New Zealand Bone and Mineral Society. Port Douglas, Australia. October 2006.
74. Briody JN, **Munns C**. The Impact of Scan Speed and Voxel Size on Peripheral QCT results. Conference: 2006 Joint Meeting of the 3rd International Osteoporosis Foundation Asia-Pacific Regional Conference on Osteoporosis and 16th Annual Meeting of the Australian and New Zealand Bone and Mineral Society. Port Douglas, Australia. October 2006.
75. **Munns CF**, Briody J, McQuade M, Little DG, Cowell CT. Effect of zoledronic acid on growth and bone mineral accrual in children. Bone 36 (2005) S35. Conference: 3rd International Conference on Children's Bone Health. Sorrento, Italy. May 2005.

76. Sahebjam, S, **Munns CF**, Rauch F, Glorieux FH. Vertebral Morphometry During Pamidronate Treatment for Pediatric Osteogenesis Imperfecta. Conference: 26th Annual Meeting of the American Society of Bone and Mineral Research. Seattle, USA. Oct 2004.
77. **Munns CF**, Rauch F, Glorieux FH. Pamidronate Treatment in Infants with Severe Osteogenesis Imperfecta: Three-Year Follow-Up Results. Conference: 26th Annual Meeting of the American Society of Bone and Mineral Research. Seattle, USA. Oct 2004.
78. **Munns CF**, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed Fracture and Osteotomy Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate. Conference: 25th Annual Meeting of the American Society of Bone and Mineral Research. Minneapolis, USA. Sept 2003.
79. Haase H.R., **Munns C.F.J.**, Hayes M.T., Batch J.A. Short Stature Homeobox Gene: Subcellular Localization of SHOX in Chondrocyte-type cells. Conference: Matrix Biology Society of Australia and New Zealand Annual Meeting. Wisemans Ferry NSW, Australia. Sept 2002.
80. **Munns C**, Flanagan S, Hayes M, Berry M, Vickers D, O'Rourke P, Rao E, Rappold G, Hyland V, Glass I, Batch J. The Spectrum of *SHOX* Haploinsufficiency Disorder: Diagnostic Markers. Conference: Australasian Paediatric Endocrine Group Annual Scientific Meeting, Gold Coast, Australia, September 2001.
81. **Munns CF**, McGill J, Perry-Keene D, Batch J. Pamidronate: Novel treatment for Carpotarsal Osteolysis. Conference: "Paediatric Endocrinology Montreal 2001" : Joint meeting of the Lawson Wilkins Pediatric Endocrine Society and the European Society of Paediatric Endocrinology, Montreal, Canada. July 2001.
82. **Munns C**, Flanagan S, Hayes M, Berry M, Vickers D, O'Rourke P, Rao E, Rappold G, Hyland V, Glass I, Batch J. SHOX: Growth Effect in Leri-Weill dyschondrosteosis. Conference: Paediatric Endocrine Genes 2000, Sydney, Australia. October 2000.
83. **Munns CF**, McGill J, Batch J, Perry-Keene D. Pamidronate in Childhood Osteoporosis. Conference: International Bone and Hormone Meeting, Hamilton Island, Australia. October 2000.
84. **Munns C**, Flanagan S, Hayes M, Berry M, Vickers D, O'Rourke P, Rao E, Rappold G, Hyland V, Glass I, Batch J. SHOX: Effect in Leri-Weill dyschondrosteosis. Conference: International Bone and Hormone Meeting, Sydney, Australia. October 2000.
85. **Munns C**, Flanagan S, Hayes M, Berry M, Vickers D, O'Rourke P, Rao E, Rappold G, Hyland V, Glass I, Batch J. Leri-Weill dyschondrosteosis : Histopathology and SHOX Immunohistochemistry. Conference: 11th International Congress of Endocrinology, Sydney, Australia. October 2000.

(v) PhD University of Queensland

PhD Thesis: "Role of the Short Stature Homeobox Gene in Skeletal Growth and Development". Supervisors: Prof Jennifer Batch, Prof Ian Glass. Awarded 2004

(vi) Invited International Presentations

1. Symposium: New Era of Management of X-linked Hypophosphatemia. APPEs 2021. Malaysia and Virtual Meeting. November 2021.
2. Symposium: Current and Future Treatment Perspectives for Osteogenesis Imperfecta. MAC 11 – Annual Congress of the Malaysian Endocrine and Metabolic Society. Virtual Meeting. July 2021.
3. Meet the Expert: Management of Hypophosphataemic Bone Disease. MAC 11 – Annual Congress of the Malaysian Endocrine and Metabolic Society. Virtual Meeting. July 2021.
4. Vitamin D Supplementation During Pregnancy and the First Year of Life. Sanofi India Educational Series. Virtual Meeting. May 2021.
5. Biologics Therapy for Perthes. International Perthes Study Group Annual Meeting. Virtual Meeting. January 2021.
6. Novel Therapeutics in Bone. ISPAE Annual Scientific Meeting. Kolkata, India. November 2019.
7. Approach to Resistant Rickets. ISPAE Annual Scientific Meeting. Kolkata, India. November 2019.
8. Current Perspectives in Diagnosis and Management of Metabolic Bone Diseases in Children. ISPAE PET Fellow School 2019. Kolkata, India. November 2019.
9. Challenge the Expert. 9th International Conference on Children's Bone Health. Salzburg, Austria, June 2019.
10. Bone fragility during childhood – beyond osteogenesis imperfecta. 9th International Conference on Children's Bone Health. Salzburg, Austria, June 2019.
11. Bone Health in Children with Chronic Disease. Continuous Medical Education Day. Hanoi, Vietnam. May 2018.
12. Multiple Fractures in Children / Osteogenesis Imperfecta. 17th NOFSA Congress. Cape Town, South Africa. March 2018.
13. Skeletal Health in Children with Chronic Disease. 17th NOFSA Congress. Cape Town, South Africa. March 2018.
14. Osteogenesis Imperfecta. OI and Paediatric Bone Health Working Group. Johannesburg, South Africa. March 2018.
15. Skeletal Health in Children with Chronic Disease. OI and Paediatric Bone Health Working Group. Johannesburg, South Africa. March 2018.
16. Nutritional Rickets. Vitamin D Standardization Program; The Road Ahead. NIH. Washington DC, USA. November 2017.
17. The Management of Osteoporosis in Children with Neuromuscular Disorders. Bone and Mineral Working Group Meeting of the 10th International Meeting of Pediatric Endocrinology. Washington DC, USA. September 2017.
18. Pediatric osteoporosis – Meet the Expert. 10th International Meeting of Pediatric Endocrinology. Washington DC, USA. September 2017.
19. Nutritional Rickets. 1st International Conference on Controversies in Vitamin D. Pisa, Italy. June 2017.
20. Bone fragility in adolescent: when to worry and what should we do? Malaysian Endocrine and Metabolic Society. Kuala Lumpur, Malaysia. May 2017.
21. Hypoparathyroidism in children. Malaysian Endocrine and Metabolic Society. Kuala Lumpur, Malaysia. May 2017.

22. Nutritional Rickets. Thailand Pediatric Endocrinology APPES CME. Bangkok, Thailand. May 2017.
23. Novel Treatment Approaches for Osteogenesis Imperfecta. 1st Asia-Pacific Bone Disorders Symposium. Melbourne, Victoria. September 2016.
24. Meet the Professor: Pediatric Osteoporosis. 9th APPES/50th JSPE Joint Scientific Meeting. Tokyo, Japan. November 2016.
25. The Birmingham consensus recommendations for prevention and treatment of rickets. International Society of Childhood and Adolescent Diabetes, Annual Scientific Meeting. India, November 2015.
26. Novel therapies for pediatric osteoporosis. International Society of Childhood and Adolescent Diabetes, Annual Scientific Meeting. India, November 2015.
27. Bone complications of childhood cancer. Combined APEG/ISPAD Scientific Meeting. Brisbane, Australia. September 2015.
28. Vitamin D Consensus Statement. 7th International Conference on Children's Bone Health. Salzburg, Austria, June 2015.
29. Duchenne and cerebral palsy. 7th International Conference on Children's Bone Health. Salzburg, Austria, June 2015.
30. Repeated Fractures in children: when is it endocrinological? Indonesian Pediatric Endocrine Society, 3rd Pediatric Endocrine Update. Bali, Indonesia, May 2015.
31. Vitamin D in sun-rich countries: do we need supplementation? Indonesian Pediatric Endocrine Society, 3rd Pediatric Endocrine Update. Bali, Indonesia, May 2015.
32. Novel Treatment Approaches for Osteogenesis Imperfecta. ENDO 2015 (Endocrine Society Annual Scientific Meeting). San Diego, CA, USA, March 2015.
33. Vitamin D and Calcium in Childhood. Training Course on Bone and Genetic Muscle Disorders. National Hospital of Pediatrics, Hanoi, Vietnam. May 2014.
34. Osteogenesis Imperfecta: Diagnosis and Management. Training Course on Bone and Genetic Muscle Disorders. National Hospital of Pediatrics, Hanoi, Vietnam. May 2014.
35. Treatment of Childhood Osteoporosis: Future Perspectives. 8th APPES/APEG Joint Scientific Meeting. Darwin, Australia. November 2014.
36. Medical therapies: present and future. 6th International Conference on Children's Bone Health, Rotterdam, Netherlands. June 2013.
37. Vitamin D and Calcium in Childhood. Training Course on Bone and Genetic Muscle Disorders. National Hospital of Pediatrics, Hanoi, Vietnam. May 2013.
38. Osteogenesis Imperfecta: Diagnosis and Management. Training Course on Bone and Genetic Muscle Disorders. National Hospital of Pediatrics, Hanoi, Vietnam. May 2013.
39. Paediatric Bone Health: Assessment and Optimisation. Continuous Medical Education Course. Children's Hospital 2, Ho Chi Minh City, Vietnam. May 2013
40. Osteogenesis imperfecta: Diagnosis and Management. Continuous Medical Education Course. Children's Hospital 2, Ho Chi Minh City, Vietnam. May 2013
41. Hypercalcaemia , hypocalcaemia and Rickets. Continuous Medical Education Course. Children's Hospital 2, Ho Chi Minh City, Vietnam. May 2013
42. Update in Osteogenesis Imperfecta. National Hospital of Pediatrics, Hanoi, Vietnam. November 2011.
43. Recent Discoveries in Pediatric Bone Health. APPES CME Meeting. Hanoi, Vietnam. November 2011.
44. Bone Health. Indonesian Pediatric Society. 15th Child Health National Congress. Manado, North Sulawesi, Indonesia. July 2011.
45. Investigation and Treatment of Paediatric Osteoporosis. Indonesian Pediatric Society. 15th Child Health National Congress. Manado, North Sulawesi, Indonesia. July 2011.

46. Management of Paediatric Osteoporosis. Sixth APPES Scientific Meeting. Xi'an, China. November 2010.
47. Recent Discoveries in Pediatric Bone Health. ASBMR – 2010 Pediatric Bone and Mineral Working Group. Vancouver, Canada. October 2010.
48. Importance of Vitamin D in Childhood and Adolescence. The 42nd International Symposium on Endocrinology & Metabolism. Vienna, Austria. May 2010
49. GI/Nutrition Literature Review and Identify Care Issues. First International Congenital Myopathies Standard of Care Conference. Stanford, USA. May 2010
50. Consensus Recommendations for GI/Nutrition Care. First International Congenital Myopathies Standard of Care Conference. Stanford, USA. May 2010
51. Investigation and Management of Pediatric Osteoporosis. International Update in Pediatric Endocrinology. Mumbai, India. February 2008.
52. Investigation and Management of Childhood Osteoporosis. 4th Biennial Scientific Meeting, Asia Pacific Paediatric Endocrine Society 2006. Pattaya, Thailand. November 2006.
53. Chronic Bone Disease in Children. APEG Annual Scientific Meeting. Auckland, New Zealand. December 2004.
54. When to Stop Bisphosphonates in Osteogenesis Imperfecta. Children's Bone Symposium. Sydney, Australia. September 2004.
55. Bisphosphonates in Type I Osteogenesis Imperfecta. Scientific Meeting on Mild OI. Chicago, USA. April 2004.
56. Genotype – Phenotype Correlations in Osteogenesis Imperfecta. Scientific Meeting on Mild OI. Chicago, USA. April 2004.
57. Natural History of Mild Osteogenesis Imperfecta. Scientific Meeting on Mild OI. Chicago, USA. April 2004.
58. SHOX: Role in Skeletal Growth and Development. University of Washington, Seattle, USA. July 2001.
59. Pamidronate Therapy in Osteogenesis Imperfecta. Shriners Hospital for Children, Montreal, Canada. February 2003.
60. SHOX: Role in Skeletal Growth and Development. Shriners Hospital for Children, Montreal, Canada. July 2001.

(vii) Invited Local Presentations

1. Burosumab Therapy In XLH. Hot Topics in Paediatric Endocrinology. APEG Annual Scientific Meeting. Mornington Peninsular. November 2021.
2. Bone Development in Children. Royal North Shore Hospital Endocrinology Grand Rounds. Sydney. June 2021.
3. Bisphosphonate therapy in Children. Paediatric Endocrine Education Symposium. Brisbane. June 2021.
4. Bone Health in Children with Chronic Disorders. Grand Rounds Queensland Children's Hospital. Brisbane. June 2021.
5. Outstanding progress achieved by CHW in enrolling patients in clinical trials. Sydney Health Partners' Annual Forum. Sydney. June 2021.
6. ZAP, Outcome of Randomised Controlled Trial. Bone and Mineral Working Group Virtual Meeting. March 2021.
7. Vitamin D supplementation during pregnancy and the first year of life. Grand Rounds. Nepean Hospital. September 2020.
8. X-linked Hypophosphataemic rickets. 30th Australian and New Zealand Bone and Mineral Society Annual Scientific Meeting. Virtual Meeting. Sept 2020.
9. Burosumab: role in management of X-linked hypophosphataemic rickets. 29th Australian and New Zealand Bone and Mineral Society Annual Scientific Meeting. Darwin, Northern Territory. Oct 2019.
10. Endocrinology – Bisphosphonate treatments: Australian Standard. Osteogenesis Imperfecta Foundation. Sydney. October 2019.
11. Vitamin D supplementation during pregnancy and the first year of life. 6th Annual Nepean Blue Mountains Clinical Paediatrics Day. Leura. October 2019.
12. Vitamin D in Pregnancy - Supplementation or not. Healthed Educational Series. Sydney, Melbourne, Adelaide and Brisbane. 2019.
13. Paediatric Bone Health. Paediatric Physiotherapy Musculoskeletal Forum. Sydney. July 2018.
14. Nutritional Rickets: A Call for Action. Australian Pharmacy Professional Conference. Gold Coast. May 2018.
15. Paediatric Osteoporosis: aetiology, diagnosis and management approached. Amgen Bone Academy. Melbourne. April 2017.
16. Paediatric Osteoporosis Diagnosis and Management. Paediatric Endocrine Update, Brisbane. 2017.
17. Metabolic Bone Disease: When Broken Does Not Mean Abuse: Child Protection Forum. Sydney, NSW. November 2016.
18. Cancer associate avascular necrosis of bone. ESA-SRA-ANZBMS Combined Scientific Meeting. Gold Coast, Queensland. August 2016.
19. Controversies in Endocrinology: International Consensus on Prevention and Management of Nutritional Rickets. APEG Annual Scientific Meeting. Alice Springs, Northern Territory. August, 2016.
20. Bone complications of childhood cancer. Combined APEG/ISPAD Scientific Meeting. Brisbane, Queensland. September 2015.
21. Bone Health in Cystic Fibrosis. 11th Australasia Cystic Fibrosis Conference. Sydney. August 2015.
22. Treatment of Childhood Osteoporosis: Future Perspectives. 8th APPES/APEG Joint Scientific Meeting. Darwin, Australia. November 2014.
23. Update on the Role of Bisphosphonate Therapy in Paediatric Orthopaedics. 24th Australian Paediatric Orthopaedic Society Annual Scientific Meeting. Noosa. Queensland. August 2014.
24. Osteogenesis Imperfecta – Diagnosis and Management. 24th Australian Paediatric Orthopaedic Society Annual Scientific Meeting. Noosa. Queensland. August 2014.

25. Metabolic Bone Disease and Fracture. Sydney Children's Hospital Grand Rounds. Sydney. August 2014.
26. Paediatric Osteoporosis: Present and Future. AIMSS Seminar and Lunch. Melbourne. February 2014.
27. Bones, Bones, Bones. SNIPS 2013. Disability Health Care in the Gong. Wollongong. August 2013.
28. Osteogenesis Imperfecta: Diagnosis and Management. Sydney Orthopaedic Update. Sydney. June 2013.
29. Paediatric Bone in Health and Disease. Australasian Academy of Paediatric Dentistry Annual Scientific Meeting. Melbourne. April 2013.
30. Bisphosphonate Therapy in Children. Australasian Academy of Paediatric Dentistry Annual Scientific Meeting. Melbourne. April 2013.
31. Paediatric Bone Health: Glucocorticoids and Rheumatic Disease. 53rd Annual Scientific Meeting of The Australian Rheumatology Association. Canberra, Australia. May 2012.
32. Vitamin D and Calcium Supplementation in Pregnancy. Annual Women's Health Update. Sydney, Adelaide and Perth. 2012.
33. Vitamin D Deficiency and calcium supplementation. Paediatric Update 2011. Sydney, Australia. October 2011.
34. Investigation and Treatment of Paediatric Osteoporosis. Paediatric Update 2011. Sydney, Australia. October 2011.
35. Vitamin D Deficiency in Childhood. Practice Paediatrics for GPs – 2011. Sydney, Australia. August 2011.
36. Bone Health in Children Following Spinal Cord Injury. SpineCare 2011. Sydney, Australia. March 2011.
37. Bisphosphonates – their usage and concerns in the young patient. ANZSPD (NSW). Sydney, Australia. March 2011.
38. Management of Paediatric Osteoporosis. APEG Annual Scientific Meeting. Adelaide, Australia. August 2010.
39. Osteoporosis in the Young. Endocrine Society of Australia Annual Seminar, Wollongong, Australia. April 2010.
40. Bone Health in DMD. Towards a Brighter Future: 2010 Neuromuscular Disorders Conference, Sydney, Australia. February 2010.
41. Dysphagia in Cerebral Palsy Workshop "Guts, Bones and Rattly Chests". Association of Doctors in Developmental Disability, Sydney. October 2009.
42. Bone Health in Childhood Disability. Australasian Faculty of Rehabilitation Medicine Annual Scientific Meeting 2007, Sydney, Australia.
43. Making Bones Strong – Leaning Towards what Really Matters. Nutrition Society of Australia, 30th Annual Scientific Meeting, Sydney, Australia. November 2006.
44. Rickets and Evaluation of Osteoporosis. Paediatric Update. Children's Hospital at Westmead. November 2006.
45. Regional Osteopenia Following Paediatric Spinal Cord Injury. Paediatric Bone Australasia, Paediatric Bone Update, Brisbane, Australia. October 2006.
46. Vitamin D Deficiency in Australian Children: Etiology and Treatment. Paediatric Bone Australasia, Paediatric Bone Update, Brisbane, Australia. October 2006.
47. Genetic Mineralization Disorders. Paediatric Bone Australasia, Paediatric Bone Update, Brisbane, Australia. October 2006.
48. Bisphosphonates in Metabolic Bone Disease. Paediatric Update. Children's Hospital at Westmead. November 2004.
49. When to Stop Bisphosphonates In OI. Paediatric Bone Symposium. Sydney, Australia. August 2004.
50. Bisphosphonates and metabolic bone disease. The Children's Hospital at Westmead Paediatric Update Conference, Sydney, Australia. November 2004.

51. Pamidronate in Paediatric Bone Disease – Improving Rehabilitation Outcomes. 10th Annual Scientific Meeting of the Australian Faculty of Rehabilitation Medicine AFRM, Brisbane, Australia. 7-10 May 2002.
52. Novel Treatments in Osteogenesis Imperfecta. University of Queensland, Brisbane, Australia. March 2002.
53. Pamidronate in Paediatric Bone Disease. Royal Children's Hospital. November 2001.